Original Article
Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma
N Engl J Med 1999; 340:1154-1161April 15, 1999
- Abstract
Background
Bulky stage IB cervical cancers have a poorer prognosis than smaller stage I cervical cancers. For the Gynecologic Oncology Group, we conducted a trial to determine whether weekly infusions of cisplatin during radiotherapy improve progression-free and overall survival among patients with bulky stage IB cervical cancer.
Methods
Women with bulky stage IB cervical cancers (tumor, ≥4 cm in diameter) were randomly assigned to receive radiotherapy alone or in combination with cisplatin (40 mg per square meter of body-surface area once a week for up to six doses; maximal weekly dose, 70 mg), followed in all patients by adjuvant hysterectomy. Women with evidence of lymphadenopathy on computed tomographic scanning or lymphangiography were ineligible unless histologic analysis showed that there was no lymph-node involvement. The cumulative dose of external pelvic and intracavitary radiation was 75 Gy to point A (cervical parametrium) and 55 Gy to point B (pelvic wall). Cisplatin was given during external radiotherapy, and adjuvant hysterectomy was performed three to six weeks later.
Results
The relative risks of progression of disease and death among the 183 women assigned to receive radiotherapy and chemotherapy with cisplatin, as compared with the 186 women assigned to receive radiotherapy alone, were 0.51 (95 percent confidence interval, 0.34 to 0.75) and 0.54 (95 percent confidence interval, 0.34 to 0.86), respectively. The rates of both progression-free survival (P<0.001) and overall survival (P=0.008) were significantly higher in the combined-therapy group at four years. In the combined-therapy group there were higher frequencies of transient grade 3 (moderate) and grade 4 (severe) adverse hematologic effects (21 percent, vs. 2 percent in the radiotherapy group) and adverse gastrointestinal effects (14 percent vs. 5 percent).
Conclusions
Adding weekly infusions of cisplatin to pelvic radiotherapy followed by hysterectomy significantly reduced the risk of disease recurrence and death in women with bulky stage IB cervical cancers.
Media in This Article
Figure 1
Kaplan–Meier Estimates of Progression-free Survival in Patients with Cervical Cancer Given Radiotherapy and Cisplatin or Radiotherapy Alone.Figure 2
Kaplan–Meier Estimates of Overall Survival in Patients with Cervical Cancer Given Radiotherapy and Cisplatin or Radiotherapy Alone.Article Activity
- Article
The American Joint Committee on Cancer1 and the International Federation of Gynecology and Obstetrics define stage IB cervical cancer as invasive cancer that is confined to the cervix, with a depth of more than 5 mm and a width of more than 7 mm. In patients with large stage IB cervical cancers, local control and survival are poorer than in patients with smaller stage I cancers, whether treated by surgery or irradiation.2-4 The optimal treatment of large stage IB cervical cancer has been a source of controversy since the late 1960s.5-9
In a previous randomized trial of combined external and intracavitary irradiation alone or followed by extrafascial hysterectomy, the Gynecologic Oncology Group found that hysterectomy did not improve survival, but it did significantly reduce the rate of relapse in the pelvic region (unpublished data). Several phase 2 studies have reported that concomitant treatment with cisplatin during radiotherapy results in faster and more complete responses and better survival than expected with radiotherapy alone.10-17 We elected to test this combination in a phase 3 trial to determine whether concurrent weekly treatment with cisplatin during radiotherapy would improve progression-free survival and survival in women with large “bulky,” or barrel-shaped, stage IB cervical cancers.
Methods
Patients
Women of any age with biopsy-proved primary squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix of stage IB (exophytic or expansile barrel-shaped tumors with a minimal diameter of 4 cm) were eligible for the study. In addition, patients could have no radiographic evidence of lymphadenopathy on computed tomographic scanning or lymphangiography, and in those with enlarged or suspicious-appearing lymph nodes, no evidence of cancer on fine-needle aspiration or histologic evaluation.
Extraperitoneal surgical staging of lymph nodes was optional. Patients with histologic evidence of lymph-node involvement were not eligible, nor were those who had previously received radiotherapy or chemotherapy or those with a history of cancer other than nonmelanoma skin cancer.
All patients were required to have a Gynecologic Oncology Group performance status of 0, 1, 2, or 3 (equivalent to Karnofsky performance scores of 90 or 100, 70 or 80, 50 or 60, and 30 or 40, respectively) and adequate bone marrow, renal function, and hepatic function. Patients were excluded from the study if they were thought to be unable to complete the planned course of therapy or the follow-up evaluations. In addition, patients had to be medically suitable for hysterectomy.
The institutions that participated in the study are listed in the Appendix. Written informed consent was obtained before entry into the study, fulfilling all institutional, state, and federal regulations.
Radiotherapy
All patients were scheduled to undergo external irradiation, intracavitary brachytherapy, and extrafascial hysterectomy, with half the patients randomly assigned to receive weekly intravenous infusions of cisplatin during the period of radiotherapy.
The prescribed regimen of radiotherapy was identical in both groups. Pelvic radiation was delivered with the four-field technique with x-ray accelerators of at least 4-MV photons at a distance of at least 100 cm. The treatment field was set to extend 3 cm beyond the known extent of disease and to encompass iliac and lower common iliac lymph nodes. Fractions of 1.8 to 2.0 Gy were delivered 5 days a week over a period of 4 1/2 to 5 weeks, for a total dose of 45 Gy. External irradiation was withheld if the white-cell count fell below 1000 per cubic millimeter and was resumed once the count rose above that level.
Low-dose brachytherapy was performed in one or two intracavitary applications after the completion of pelvic radiotherapy. Standard Fletcher–Suit or Henschke applicators were used. The dose to point A (a reference location 2 cm lateral and 2 cm superior to the cervical os) was 30 Gy, for a cumulative dose of 75 Gy, and the cumulative dose to point B (the pelvic wall) was 55 Gy.
Chemotherapy
Cisplatin was given intravenously once a week at a dose of 40 mg per square meter of body-surface area, with the total dose not to exceed 70 mg per week. A maximum of six doses of cisplatin was given. The final dose could be given during a patient's hospitalization for intracavitary brachytherapy.
Treatment with cisplatin was withheld if the total white-cell count fell below 3000 per cubic millimeter or if creatinine clearance fell below 50 ml per minute.
Hysterectomy
Extrafascial hysterectomy was performed three to six weeks after the completion of radiotherapy. The corpus and cervix were removed but not contiguous parametrial tissue. The uterine vessels were transected at the uterine wall medial to the ureters, which were not unroofed. No vaginal cuff was removed.
Quality Control and Follow-up
Patients' medical records, films, and pathology slides were reviewed by the appropriate Gynecologic Oncology Group committees. The Radiological Physics Center in Houston coordinated the reviews of radiotherapy.
Patients were evaluated every three months for the first two years and then semiannually for three additional years. Adverse effects were reported in accordance with the Gynecologic Oncology Group criteria.18
Outcome
The primary end points were progression-free survival and survival. Progression-free survival was calculated from the date of entry into the study to the date of disease recurrence, death, or the last follow-up visit. Survival was calculated from the date of entry into the study to the date of death or the last follow-up visit. Recurrences were classified as local if they were detected in the pelvis, cervix, or vagina and as distant if they were detected in extrapelvic locations. The hysterectomy specimens were evaluated for evidence of cancer.
Statistical Analysis
We estimated that 173 patients were needed in each treatment group in order to be able to detect a 40 percent decrease in the recurrence rate in the group given radiotherapy and chemotherapy. The design called for a final analysis when 56 events (recurrences or deaths) had occurred in patients receiving the control regimen (radiotherapy alone) and provided the study with a statistical power of 80 percent with use of the log-rank test and a one-sided significance level of 0.05.19 At the time of this analysis, 69 patients in the group receiving the control regimen had had a recurrence of disease and 49 had died — 88 percent of the number of deaths needed for a final analysis of survival. Therefore, because of the large difference in outcome between the two groups and the similarity in the rates of progression-free survival and survival within each group, this analysis is the final analysis of survival.
Randomization was carried out by a block arrangement; the treatment assignments were stratified according to center and to whether para-aortic lymph nodes were evaluated surgically, with approximately equal numbers of patients assigned to each group. Life-table estimates were calculated according to the method of Kaplan and Meier.20 The difference between groups in survival and progression-free survival was evaluated with use of the log-rank test21 according to the intention-to-treat principle. The Cox model was used to evaluate the difference between treatment regimens, adjust for prognostic factors,22 and estimate the relative likelihood (and 95 percent confidence intervals) of survival and progression-free survival. Differences between groups in the severity of adverse effects and the frequency of hysterectomy specimens that were negative for cancer were evaluated with use of Pearson's chi-square test.23 All reported P values are two-tailed.
Two scheduled interim analyses were conducted during the enrollment phase of the trial: the first was conducted after 29 recurrences had been reported, and the second after 47 recurrences had been reported. The first stopping rule was chosen to reject the null hypothesis at the 1 percent level, whereas the second was chosen so that the level of rejection for both interim tests was 2 percent. This interim testing increased the value of the type I error from the conventional 5 percent to 6 percent. To simplify presentation, the P values were not adjusted for the results of the two interim analyses.
Results
Characteristics of the Patients
From February 1992 to April 1997, a total of 374 women were enrolled in the study at 48 Gynecologic Oncology Group institutions. Four were subsequently excluded after a central review by the pathology committee found that the specimen was inadequate for evaluation in the case of one patient, the primary lesion had been misidentified in the case of one patient, the cell type had been misidentified in the case of one patient, and the stage of the tumor had been overestimated in the case of one patient. An additional patient was also excluded because she had received radiotherapy before entry. Three of these patients had been randomly assigned to receive radiotherapy alone, and two had been assigned to receive radiotherapy and concomitant treatment with cisplatin. Thus, a total of 369 patients were evaluated, 186 in the radiotherapy group and 183 in the combined-therapy group.
Pretreatment surgical evaluation of para-aortic lymph nodes was optional and was performed in 13 patients (7 percent) assigned to radiotherapy alone and 14 patients (8 percent) assigned to radiotherapy and cisplatin. There were no significant differences in demographic or tumor characteristics between the two groups (Table 1Table 1
Characteristics of the Patients.). All patients had primary cervical cancers that were at least 4 cm in diameter, and the distribution of the tumors according to size was similar in the two groups. There was a slightly higher percentage of patients with grade 3 tumors in the combined-therapy group (38 percent, vs. 31 percent in the radiotherapy group).Four patients assigned to the cisplatin regimen (2 percent) received no cisplatin. A total of 164 patients (90 percent) received four or more courses of cisplatin. The median weekly dose of cisplatin was 39.0 mg per square meter (10th and 90th percentiles, 32.3 and 40.3, respectively; range, 0 to 49.7).
One patient assigned to receive radiotherapy alone and two patients assigned to receive radiotherapy and cisplatin refused to undergo radiotherapy. Otherwise, compliance with radiotherapy with respect to the dose, the volume, and the total treatment was good and was similar between the two groups (Table 2Table 2
Characteristics of Radiotherapy.). The median total treatment time was 50 days in both groups (Table 2).Extrafascial hysterectomy was performed after radiotherapy in 168 patients (90 percent) in the group given radiotherapy alone and 175 patients (96 percent) in the group given radiotherapy and cisplatin. More patients in the group given radiotherapy alone refused to undergo the operation (nine, vs. five in the combined-therapy group), and more patients in this group also had an early recurrence (eight vs. two). There were significantly more hysterectomy specimens without detectable cancer in the combined-therapy group than in the group given radiotherapy alone (52 percent vs. 41 percent, P=0.04).
Adverse Effects
There were no treatment-related deaths, but 64 patients (35 percent) in the combined-therapy group had grade 3 (moderate) or grade 4 (severe) adverse effects, as compared with 25 patients (13 percent) in the group given radiotherapy alone. These reactions consisted almost exclusively of transient hematologic effects (39 and 3 patients in the respective groups) and gastrointestinal effects (26 and 9 patients) (Table 3Table 3
Adverse Effects.). Grade 3 hematologic toxicity was defined as a total white-cell count of less than 2000 per cubic millimeter, and grade 4 as a total white-cell count of less than 1000 per cubic millimeter. Grade 3 gastrointestinal toxicity was defined as intractable vomiting despite treatment with antiemetic drugs that ultimately required hospitalization, and grade 4 as dehydration, gastrointestinal bleeding, or both. Very few patients required surgical intervention for obstruction or formation of a fistula, and these patients were equally divided between the two groups. The frequency of grade 1 (minimal) and grade 2 (mild) genitourinary and neurologic adverse effects was higher in the combined-therapy group.Progression-Free Survival
The disease recurred in 69 patients in the group given radiotherapy alone (37 percent) and 38 patients given radiotherapy and cisplatin (21 percent) (Table 4Table 4
Rates of Disease Progression and Death.). This difference predominantly reflects the fact that there were fewer local recurrences in the combined-therapy group (16, vs. 39 in the radiotherapy group). At the time of this analysis, the rate of progression-free survival was significantly higher among patients in the combined-therapy group (P<0.001 by the log-rank test) (Figure 1Figure 1Kaplan–Meier Estimates of Progression-free Survival in Patients with Cervical Cancer Given Radiotherapy and Cisplatin or Radiotherapy Alone.). The relative risk of recurrence in the combined-therapy group as compared with the group given radiotherapy alone was 0.51 (95 percent confidence interval, 0.34 to 0.75).Survival
The median duration of follow-up was 36 months. Forty-nine of the patients in the group given radiotherapy alone died of cervical cancer (26 percent), as compared with 27 of the patients in the group given radiotherapy and cisplatin (15 percent) (Table 4). One patient who received cisplatin died after an automobile accident; she had no evidence of cancer at her last examination. The relative risk of death in the combined-therapy group as compared with the group given radiotherapy alone was 0.54 (95 percent confidence interval, 0.34 to 0.86). The three-year survival rates were 74 percent in the group given radiotherapy alone and 83 percent in the combined-therapy group (P=0.008 by the log-rank test) (Figure 2Figure 2
Kaplan–Meier Estimates of Overall Survival in Patients with Cervical Cancer Given Radiotherapy and Cisplatin or Radiotherapy Alone.). The numbers of patients who were alive at the time of this analysis but in whom disease had recurred were 20 and 11, respectively.Prognostic Factors
Cox multiple regression analysis showed that the size of the tumor as assessed by physical examination and the histologic grade of the tumor were both significant prognostic factors. Adjustment for these factors had no significant effect on the differences between the groups in survival and progression-free survival.
Discussion
The treatment of women with bulky stage IB cervical cancers has historically been only partially satisfactory, with survival rates of 70 to 75 percent, substantially below the rates of 88 to 92 percent expected with smaller stage IB cancers. The recognition, in some centers, that patients with bulky stage IB cancers had higher rates of recurrent disease within the cervical area led to the inclusion of adjuvant extrafascial hysterectomy in the treatment regimen for these women.5,6 This approach was, however, associated with considerable morbidity.24
The use of extrafascial hysterectomy after radiotherapy has gradually been abandoned,25 but there has continued to be disagreement about the value of the operation.7,8 This controversy stimulated an earlier Gynecologic Oncology Group trial in which patients were randomly assigned to undergo either hysterectomy after radiotherapy or radiotherapy alone (unpublished data). In 1992, when the current study was initiated, complete data on survival in the earlier trial were not available, but an early analysis showed a significantly lower rate of relapses in the pelvic region among women who underwent hysterectomy. Therefore, we chose to test the value of concurrent treatment with cisplatin during radiotherapy followed by hysterectomy as compared with that of radiotherapy alone followed by hysterectomy.
Like others,9,26 we found that the size of the tumor was an important prognostic factor. All our patients had cervical cancers of at least 4 cm in diameter, and the distribution of the tumors according to size was similar in the two treatment groups.
The role of chemotherapy in the treatment of locally advanced cervical cancers has been uncertain. Various drugs have been used in clinical trials and increasingly in clinical practice in the past 15 years.10-27 The possibility that these drugs may have additive effects, regardless of the mechanism, when given concurrently with radiotherapy has been the subject of study. Cisplatin potentiates the sublethal damage induced by radiation28 and inhibits the repair of potentially lethal radiation-induced damage.29
Weekly treatment with cisplatin during radiotherapy has been assessed in several phase 2 studies.11-15 The promising results of these studies as well as the fact that this combination is well tolerated and easy to administer on an outpatient basis led us to evaluate it in this trial.
Both cisplatin and fluorouracil are active against cancer of the cervix in patients with recurrent disease.30,31 The effect of these two drugs in combination with radiotherapy was compared with the effect of hydroxyurea and radiotherapy in a randomized phase 3 trial by the Gynecologic Oncology Group involving patients with cervical cancer of stages IIB through IVA (unpublished data). In that study, the combination of concurrent radiotherapy and cisplatin-containing chemotherapy was superior to treatment with hydroxyurea and radiotherapy. The results of a subsequent trial involving similar patients are reported by Rose et al.32 in this issue of the Journal. They compared treatment with radiation and hydroxyurea, treatment with radiation and weekly cisplatin, and treatment with radiation and hydroxyurea, cisplatin, and fluorouracil and found that the rate of relapse-free survival was significantly higher in both regimens containing cisplatin.
In addition to these three trials, two other randomized trials have also found that combining radiotherapy and cisplatin-containing chemotherapy improves survival and disease-free survival.32 The Radiation Therapy Oncology Group study, whose results appear elsewhere in this issue of the Journal, 33 compared pelvic and para-aortic radiotherapy with pelvic radiotherapy in combination with cisplatin and fluorouracil in patients with clinical stage IB through IVA cervical cancer. The Southwest Oncology Group study compared pelvic radiotherapy alone with pelvic radiotherapy in combination with fluorouracil and cisplatin in high-risk patients with involvement of lymph nodes or surgical margins who had undergone radical hysterectomy for cervical cancer stage IA2, IB, or IIA (unpublished data). Both studies found that survival was increased by the use of radiotherapy in combination with cisplatin-containing chemotherapy.
In our trial the only difference in the protocols for the two groups was the use of weekly infusions of cisplatin during radiotherapy for bulky stage IB cervical cancers. The risk of recurrence and death was significantly reduced by concurrent treatment with cisplatin and radiotherapy. This difference appeared to be due to the lower rate of relapses in the pelvic region in the combined-therapy group. Although this regimen was also associated with higher rates of adverse effects, these effects consisted predominantly of transient hematologic and gastrointestinal effects, with no evidence of an increase in other serious effects. There was no evidence of a difference in the frequencies of late adverse effects between the groups.
Of the 369 eligible patients in our study who were scheduled to undergo hysterectomy after the completion of radiotherapy, 93 percent did undergo the surgery. We believe that the value of hysterectomy in these patients is doubtful. In the earlier Gynecologic Oncology Group study that assessed the value of extrafascial hysterectomy after radiotherapy, surgery was associated with a significant reduction in the rate of relapses in the pelvic region, but the overall risk of recurrence was not significantly reduced (relative risk, 0.76; 95 percent confidence interval, 0.52 to 1.12) and there was no significant difference in survival (relative risk of death, 0.91). It is reasonable to conclude on the basis of these results and our results that the elimination of hysterectomy from both regimens would not have affected the increase in survival associated with the use of cisplatin. Therefore, radiotherapy in combination with treatment with cisplatin should be adequate for patients with bulky stage IB cervical cancer.
The five randomized trials of cervical cancer that we have discussed involve different stages of cervical cancer and combinations of treatment, but they share a common result: all five studies found that concomitant treatment with cisplatin and radiotherapy led to better outcomes than radiotherapy alone or in combination with treatments that did not include cisplatin. This remarkable consistency offers a compelling reason to consider cisplatin therapy in combination with radiotherapy as a new standard of care for patients with bulky stage IB, stage IIB through IVA, and high-risk cervical cancers.
Presented at the Society of Gynecologic Oncologists, Orlando, Fla., February 9, 1998.
Supported by grants from the National Cancer Institute (CA 27469, to the Gynecologic Oncology Group Administrative Office, and CA 37517, to the Gynecologic Oncology Group Statistical Office).
We are indebted to the Radiological Physics Center for ensuring that the radiation doses delivered to all patients in this study were clinically similar; for reviewing all technical aspects of the treatment, verifying the reported doses, and participating in the clinical evaluation of all patients; and for monitoring the calibration of the dosimeters used and for on-site evaluations of selected institutions as needed.
Source Information
From the Department of Radiation Oncology, Albany Medical College, Albany, N.Y. (H.M.K.); the Gynecologic Oncology Group Statistical Office, Roswell Park Cancer Institute, Buffalo, N.Y. (B.N.B.); the Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis (F.B.S.); the Division of Gynecologic Oncology, University of Southern California School of Medicine, Los Angeles (L.I.M.); the Division of Gynecologic Oncology, Eastern Virginia Medical School, Norfolk (W.E.C.); the Department of Obstetrics and Gynecology, University of Tennessee College of Medicine at Chattanooga, and the Department of Gynecologic Oncology, Erlanger Medical Center, Chattanooga (C.L.S.); the Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences, Oklahoma City (J.L.W.); and the Department of Pathology, Washington University School of Medicine, St. Louis (D.G.).
Address reprint requests to Denise Mackey at the GOG Administrative Office, Suite 1945, 1234 Market St., Philadelphia, PA 19107, or at dmackey@acog.org.
Appendix
The following Gynecologic Oncology Group institutions participated in the study: University of Alabama, Oregon Health Sciences University, Duke University Medical Center, Abington Memorial Hospital, Walter Reed Army Medical Center, Wayne State University, University of Minnesota Medical School, University of Southern California, University of Mississippi, Colorado Gynecologic Oncology Group, University of California at Los Angeles, University of Washington, University of Miami School of Medicine, Milton S. Hershey Medical Center, Georgetown University Hospital, University of Cincinnati Medical Center, University of North Carolina, University of Iowa Hospitals and Clinics, Indiana University Medical Center, Bowman Gray School of Medicine, State University of New York–Syracuse, Albany Medical College, University of California Medical Center at Irvine, Tufts–New England Medical Center, Rush–Presbyterian–St. Luke's Medical Center, Stanford University Medical Center, State University of New York at Brooklyn, University of Kentucky, Eastern Virginia Medical School, Cleveland Clinic Foundation, Johns Hopkins Oncology Center, State University of New York at Stony Brook, Eastern Pennsylvania Gynecology–Oncology Center, Cooper Hospital, University Medical Center, Columbus Cancer Council–Ohio State, Fox Chase Cancer Center, Medical University of South Carolina, Women's Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, Tacoma General Hospital, Thomas Jefferson University Hospital, Case Western Reserve University, Tampa Bay Cancer Consortium, and New York Hospital–Cornell Medical Center.
- References
References
1
Cervix uteri. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds. Manual for staging of cancer. 4th ed. Philadelphia: J.B. Lippincott, 1992:155-60.
2
Delgado G ,Bundy BN ,Fowler WC Jr , et al. A prospective surgical study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;35:314-320
CrossRef | Web of Science | Medline3
Homesley HD ,Raben M ,Blake DD , et al. Relationship of lesion size to survival in patients with stage IB squamous cell carcinoma of the cervix uteri treated by radiation therapy. Surg Gynecol Obstet 1989;150:529-5314
Perez CA ,Grigsby PW ,Nene SM , et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer 1992;69:2796-2806
CrossRef | Web of Science | Medline5
Durrance FY ,Fletcher GH ,Rutledge FN . Analysis of central recurrent disease in stages I and II squamous cell carcinomas of the cervix on intact uterus. AJR Am J Roentgenol 1969;106:831-838
Web of Science6
Rutledge FN ,Wharton JT ,Fletcher GH . Clinical studies with adjunctive surgery and irradiation therapy in the treatment of carcinoma of the cervix. Cancer 1976;38:596-602
CrossRef | Web of Science | Medline7
Gallion HH ,van Nagell JR Jr ,Donaldson ES , et al. Combined radiation therapy and extra-fascial hysterectomy in the treatment of stage IB barrel-shaped cervical cancer. Cancer 1985;56:262-265
CrossRef | Web of Science | Medline8
Perez CA ,Breaux S ,Askin F ,Camel HM ,Powers WE . Irradiation alone or in combination with surgery in stage IB and IIA carcinoma of the uterine cervix: a nonrandomized comparison. Cancer 1979;43:1062-1072
CrossRef | Web of Science | Medline9
Delgado G ,Bundy B ,Zaino R ,Sevin BU ,Creasman WT ,Major F . Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352-357
CrossRef | Web of Science | Medline10
Monyak DJ, Twiggs LB, Potish RA, et al. Tolerance and preliminary results of simultaneous therapy with radiation and cisplatin for advanced cervical cancer. In: Conference on the interaction of radiation therapy and chemotherapy. NCI monographs. No. 6. Washington, D.C.: Government Printing Office, 1988:369-73. (NIH publication no. 88-2939.)
11
Runowicz CD ,Wadler S ,Rodriguez-Rodriguez L , et al. Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. Gynecol Oncol 1989;34:395-401
CrossRef | Web of Science | Medline12
Malfetano JH ,Keys H . Aggressive multimodality treatment for cervical cancer with paraaortic lymph node metastases. Gynecol Oncol 1991;42:44-47
CrossRef | Web of Science | Medline13
Malfetano JH ,Keys H ,Kredentser D ,Cunningham M ,Kotlove D ,Weiss L . Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. Cancer 1993;71:3703-3706
CrossRef | Web of Science | Medline14
Malfetano JH ,Keys H ,Cunningham MJ ,Gibbons S ,Ambros R . Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma. Gynecol Oncol 1997;67:203-207
CrossRef | Web of Science | Medline15
Malviya VK ,Deppe G ,Kim Y ,Gove N . Concurrent radiation therapy, cis-platinum, and mitomycin C in patients with poor prognosis cancer of the cervix: a pilot study. Am J Clin Oncol 1989;12:434-437
CrossRef | Web of Science | Medline16
Chang HC ,Lai CH ,Chen MS ,Chao AS ,Chen LH ,Soong YK . Preliminary results of concurrent radiotherapy and chemotherapy with cis-platinum, vincristine, and bleomycin in bulky, advanced cervical carcinoma: a pilot study. Gynecol Oncol 1992;44:182-188
CrossRef | Web of Science | Medline17
Lin J ,Ho ES ,Jan JS ,Yang CH ,Liu PS . High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1996;61:101-108
CrossRef | Web of Science | Medline18
Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G, ed. Chemotherapy of gynecologic cancer. 2nd ed. New York: Alan R. Liss, 1990:63-97.
19
Schoenfeld DA . Sample-size formula for the proportional-hazards regression model. Biometrics 1983;39:499-503
CrossRef | Web of Science | Medline20
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science21
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline22
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22023
Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames: Iowa State University Press, 1967.
24
O'Quinn AG ,Fletcher GH ,Wharton JT . Guidelines for conservative hysterectomy after irradiation. Gynecol Oncol 1980;9:68-79
CrossRef | Web of Science | Medline25
Thoms WW Jr ,Eifel PJ ,Smith TL , et al. Bulky endocervical carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys 1992;23:491-499
CrossRef | Web of Science | Medline26
Stehman FB ,Bundy BN ,DiSaia PJ ,Keys HM ,Larson JE ,Fowler WC . Carcinoma of the cervix treated with irradiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991;67:2776-2785
CrossRef | Web of Science | Medline27
Heaton D ,Yordan E ,Reddy S , et al. Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy. Gynecol Oncol 1990;38:323-327
CrossRef | Web of Science | Medline28
Carde P ,Laval F . Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 1981;7:929-933
CrossRef | Web of Science | Medline29
Wallner KE ,Li GC . Effect of cisplatin resistance on cellular radiation response. Int J Radiat Oncol Biol Phys 1987;13:587-591
CrossRef | Web of Science | Medline30
Bonomi P ,Blessing JA ,Stehman FB ,DiSaia PJ ,Walton L ,Major FJ . Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-1085
Web of Science | Medline31
Malkasian GD Jr ,Decker DG ,Jorgensen EO . Chemotherapy of carcinoma of the cervix. Gynecol Oncol 1977;5:109-120
CrossRef | Web of Science | Medline32
Rose PG ,Bundy BN ,Watkins EB , et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153
Full Text | Web of Science | Medline33
Morris M ,Eifel PJ ,Lu J , et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143
Full Text | Web of Science | Medline
- Citing Articles (515)
Citing Articles
1
Tetsuo Nonaka, Yuko Nakayama, Nobutaka Mizoguchi, Ryo Onose, Hisamori Kato, Hiroki Nakayama. (2012) Definitive radiation therapy for invasive carcinoma of the vagina: impact of high-dose rate intracavitary brachytherapy. International Journal of Clinical Oncology
CrossRef2
Won-Moo Lee, Sang-Il Park, Beob-Jong Kim, Moon-Hong Kim, Seok-Cheol Choi, Eui-Don Lee, Sang-Young Ryu. (2012) Clinicopathologic factors for central recurrence in patients with locally advanced bulky cervical cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology
CrossRef3
B. Wörmann. (2012) Systemische Therapie in einem kurativen multimodalen Konzept. Der Onkologe
CrossRef4
Akila N. Viswanathan, Jennifer Moughan, William Small, Charles Levenback, Revathy Iyer, Sharon Hymes, Adam P. Dicker, Brigitte Miller, Beth Erickson, David K. Gaffney. (2012) The Quality of Cervical Cancer Brachytherapy Implantation and the Impact on Local Recurrence and Disease-Free Survival in Radiation Therapy Oncology Group Prospective Trials 0116 and 0128. International Journal of Gynecological Cancer 22:1, 123-131
CrossRef5
Sushil Beriwal, D. Jeffrey Demanes, Beth Erickson, Ellen Jones, Jennifer F. De Los Santos, Robert A. Cormack, Catheryn Yashar, Jason J. Rownd, Akila N. Viswanathan. (2012) American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. Brachytherapy 11:1, 68-75
CrossRef6
Akila N. Viswanathan, Bruce Thomadsen. (2012) American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles. Brachytherapy 11:1, 33-46
CrossRef7
Haihua Xiao, Dongfang Zhou, Shi Liu, Yonghui Zheng, Yubin Huang, Xiabin Jing. (2012) A complex of cyclohexane-1,2-diaminoplatinum with an amphiphilic biodegradable polymer with pendant carboxyl groups. Acta Biomaterialia
CrossRef8
Jie Tang, Yanxiang Tang, Jun Yang, Si Huang. (2012) Chemoradiation and Adjuvant Chemotherapy in advanced cervical adenocarcinoma. Gynecologic Oncology
CrossRef9
Kanyarat Katanyoo, Siriwan Tangjitgamol, Marisa Chongthanakorn, Thanatip Tantivatana, Sumonmal Manusirivithaya, Kanisa Rongsriyam, Atchima Cholpaisal. (2011) Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecologic Oncology 123:3, 571-576
CrossRef10
Akila N. Viswanathan. (2011) Advances in the Use of Radiation for Gynecologic Cancers. Hematology/Oncology Clinics of North America
CrossRef11
Virginia Benito, Amina Lubrano, Octavio Arencibia, Miguel Andújar, Beatriz Pinar, Norberto Medina, Juan Miguel Falcón, Orlando Falcón. (2011) Laparoscopic Extraperitoneal Para-Aortic Lymphadenectomy in the Staging of Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer1
CrossRef12
Peter G. Rose, Michael W. Sill, D. Scott McMeekin, Amina Ahmed, Ritu Salani, S. Diane Yamada, Aaron Wolfson, Nancy Fusco, Paula M. Fracasso. (2011) A Phase I Study of Concurrent Weekly Topotecan and Cisplatin Chemotherapy with Whole Pelvic Radiation Therapy in Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology
CrossRef13
Glenn E. Bigsby, Robert W. Holloway, Sarfraz Ahmad, Michael D. Sombeck, George Ebra, Neil J. Finkler. (2011) Chemoradiation with adjuvant hysterectomy for stage IB-2 cervical cancer: a 10-year experience. Gynecological Surgery
CrossRef14
Arunkumar Anandharaj, Senthilkumar Cinghu, Won-Dong Kim, Jae-Ran Yu, Woo-Yoon Park. (2011) Fused Toes Homolog modulates radiation cytotoxicity in uterine cervical cancer cells. Molecular Biology Reports 38:8, 5361-5370
CrossRef15
Sang-Young Ryu, Won-Moo Lee, Kidong Kim, Sang-Il Park, Beob-Jong Kim, Moon-Hong Kim, Seok-Cheol Choi, Chul-Koo Cho, Byung-Ho Nam, Eui-Don Lee. (2011) Randomized Clinical Trial of Weekly vs. Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 81:4, e577-e581
CrossRef16
David K. Gaffney, Beth A. Erickson-Wittmann, Anuja Jhingran, Nina A. Mayr, Ajmel A. Puthawala, David Moore, Gautam G. Rao, William Small, Mahesh A. Varia, Aaron H. Wolfson, Catheryn M. Yashar, William Yuh, Higinia Rosa Cardenes. (2011) ACR Appropriateness Criteria® on Advanced Cervical Cancer Expert Panel on Radiation Oncology—Gynecology. International Journal of Radiation Oncology*Biology*Physics 81:3, 609-614
CrossRef17
Sarah M. McGuire, Yusuf Menda, Laura L. Boles Ponto, Brandie Gross, John Buatti, John E. Bayouth. (2011) 3’-deoxy-3’-[18F]fluorothymidine PET Quantification of Bone Marrow Response to Radiation Dose. International Journal of Radiation Oncology*Biology*Physics 81:3, 888-893
CrossRef18
Tomoko Kazumoto, Shingo Kato, Harushige Yokota, Youko Hasumi, Nao Kino, Kouji Horie, Daisaku Yoshida, Tatsuji Mizukami, Yoshihiro Saito. (2011) Is a Low Dose of Concomitant Chemotherapy With Extended-Field Radiotherapy Acceptable as an Efficient Treatment for Cervical Cancer Patients With Metastases to the Para-Aortic Lymph Nodes?. International Journal of Gynecological Cancer 21:8, 1465-1471
CrossRef19
J. Leseur, A. Devillers, D. Williaume, E. Le Prisé, C. Fougerou, C. Bouriel, J. Levêque, E. Monpetit, J. Blanchot, R. de Crevoisier, E. Garin. (2011) Tomographie par émission de positons au (18F)-fluorodésoxyglucose dans les cancers du col utérin : évaluation ganglionnaire et valeur pronostique/prédictive des données de la tumeur primitive. Cancer/Radiothérapie
CrossRef20
Sanghyuk Song, Changhoon Song, Hak Jae Kim, Hong-Gyun Wu, Jin Ho Kim, Noh-Hyun Park, Yong-Sang Song, Jae Weon Kim, Soon-Beom Kang, Sung W. Ha. (2011) 20year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: Impact of treatment period and concurrent chemotherapy. Gynecologic Oncology
CrossRef21
Pierre Loubeyre, Isabelle Navarria, Manuela Undurraga, Alexandre Bodmer, Osman Ratib, Christoph Becker, Patrick Petignat. (2011) Is imaging relevant for treatment choice in early stage cervical uterine cancer?. Surgical Oncology
CrossRef22
Gabriela Studer, Michelle Brown, Eveline Barata Salgueiro, Hildegard Schmückle, Natalie Romancuk, Gisela Winkler, Soon Jae Lee, Ariane Sträuli, Beatrix Kissling, Reinhard Dummer, Christoph Glanzmann. (2011) Grade 3/4 Dermatitis in Head and Neck Cancer Patients Treated With Concurrent Cetuximab and IMRT. International Journal of Radiation Oncology*Biology*Physics 81:1, 110-117
CrossRef23
Wen Zhang, Jia Sheng, Zhen Huang. 2011. Structures and Functions of Nucleic Acids Modified With S, Se, and Te and Complexed with Small Molecules. , 101-141.
CrossRef24
Dirk Michael Forner, Bjoern Lampe. (2011) Exenteration as a primary treatment for locally advanced cervical cancer: long-term results and prognostic factors. American Journal of Obstetrics and Gynecology 205:2, 148.e1-148.e6
CrossRef25
José Pérez-Regadera, Alfonso Sánchez-Muñoz, Javier De-la-Cruz, Claudio Ballestín, David Lora, Rosa García-Martín, Amalia Sotoca, Elisabeth Pérez-Ruiz, Eduardo Lanzós. (2011) Impact of Epidermal Growth Factor Receptor Expression on Disease-Free Survival and Rate of Pelvic Relapse in Patients With Advanced Cancer of the Cervix Treated With Chemoradiotherapy. American Journal of Clinical Oncology 34:4, 395-400
CrossRef26
Michael D. Hasselle, Brent S. Rose, Joel D. Kochanski, Sameer K. Nath, Rounak Bafana, Catheryn M. Yashar, Yasmin Hasan, John C. Roeske, Arno J. Mundt, Loren K. Mell. (2011) Clinical Outcomes of Intensity-Modulated Pelvic Radiation Therapy for Carcinoma of the Cervix. International Journal of Radiation Oncology*Biology*Physics 80:5, 1436-1445
CrossRef27
Marta E. Alberto, Valeria Butera, Nino Russo. (2011) Which One among the Pt-Containing Anticancer Drugs More Easily Forms Monoadducts with G and A DNA Bases? A Comparative Study among Oxaliplatin, Nedaplatin, and Carboplatin. Inorganic Chemistry 50:15, 6965-6971
CrossRef28
Jonas van de Lande, Silvia von Mensdorff-Pouilly, Roelof G. Lettinga, Jurgen M. Piek, Rene H.M. Verheijen. (2011) Open Versus Laparoscopic Pelvic Lymph Node Dissection in Early Stage Cervical Cancer. International Journal of Gynecological Cancer1
CrossRef29
Jin Hwa Hong, Joong Sub Choi, Jung Hun Lee, Chang Eop Son, Seung Wook Jeon, Jong Woon Bae, Jeong Min Eom. (2011) Comparison of Survival and Adverse Events between Women with Stage IB1 and Stage IB2 Cervical Cancer Treated by Laparoscopic Radical Vaginal Hysterectomy. Annals of Surgical Oncology
CrossRef30
Chien-Chih Chen, Jin-Ching Lin, Jian-Sheng Jan, Shih-Chu Ho, Lily Wang. (2011) Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecologic Oncology 122:1, 9-13
CrossRef31
Richard Pötter, Petra Georg, Johannes C.A. Dimopoulos, Magdalena Grimm, Daniel Berger, Nicole Nesvacil, Dietmar Georg, Maximilian P. Schmid, Alexander Reinthaller, Alina Sturdza, Christian Kirisits. (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiotherapy and Oncology 100:1, 116-123
CrossRef32
Abhirami Hallock, Kathleen Surry, Deidre Batchelar, Lauren VanderSpek, Jasper Yuen, Alex Hammond, John Radwan, Brian Yaremko, George Rodrigues, David D'Souza. (2011) An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: A single institution experience. Practical Radiation Oncology 1:3, 173-181
CrossRef33
Ana Reig, Ismael Membrive, Palmira Foro, Xavier Sanz, Núria Rodríguez, Joan Lozano, Martí Lacruz, Jaume Quera, Enric Fernández-Velilla, Manuel Algara. (2011) Long-term results and prognostic factors of patients with cervical carcinoma treated with concurrent chemoradiotherapy. Clinical and Translational Oncology 13:7, 504-508
CrossRef34
Susan Davidson. (2011) Treatment for advanced cervical cancer: Impact on quality of life. Critical Reviews in Oncology/Hematology 79:1, 24-30
CrossRef35
Hee Seung Kim, Ji Hyun Kim, Hyun Hoon Chung, Hak Jae Kim, Yong Beom Kim, Jae Weon Kim, Noh Hyun Park, Yong Sang Song, Soon-Beom Kang. (2011) Significance of numbers of metastatic and removed lymph nodes in FIGO stage IB1 to IIA cervical cancer: Primary surgical treatment versus neoadjuvant chemotherapy before surgery. Gynecologic Oncology 121:3, 551-557
CrossRef36
Peter G. Rose, Shamshad Ali, Charles W. Whitney, Rachelle Lanciano, Frederick B. Stehman. (2011) Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: A Gynecologic Oncology Group study. Gynecologic Oncology 121:3, 542-545
CrossRef37
Silvia Rodríguez Villalba, Carmen Díaz-Caneja Planell, José Manuel Cervera Grau. (2011) Current opinion in cervix carcinoma. Clinical and Translational Oncology 13:6, 378-384
CrossRef38
Aditi Bhatt, Shravan Kumar Chinnikatti, B. S. Ajaikumar. (2011) Management of recurrent cancer of the uterine cervix. Oncology Reviews 5:2, 109-117
CrossRef39
Benjamin T. Gielda, Anand P. Shah, James C. Marsh, Joseph P. Smart, Damian Bernard, Jacob Rotmensch, Katherine L. Griem. (2011) Helical Tomotherapy Delivery of an IMRT Boost in Lieu of Interstitial Brachytherapy in the Setting of Gynecologic Malignancy: Feasibility and Dosimetric Comparison. Medical Dosimetry 36:2, 206-212
CrossRef40
Yi-Ting Huang, Chun-Chieh Wang, Chien-Sheng Tsai, Chyong-Huey Lai, Ting-Chang Chang, Hung-Hsueh Chou, Swei Hsueh, Chien-Kuang Chen, Steve P. Lee, Ji-Hong Hong. (2011) Long-Term Outcome and Prognostic Factors for Adenocarcinoma/Adenosquamous Carcinoma of Cervix After Definitive Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 80:2, 429-436
CrossRef41
Elizabeth L. Jewell, Michael Smrtka, Gloria Broadwater, Fidel Valea, Debra M. Davis, Kimberly C. Nolte, Renea Valea, Evan R. Myers, Gregory Samsa, Laura J. Havrilesky. (2011) Utility Scores and Treatment Preferences for Clinical Early-Stage Cervical Cancer. Value in Health 14:4, 582-586
CrossRef42
John Farley, Michael W. Sill, Michael Birrer, Joan Walker, Russell J. Schilder, J. Tate Thigpen, Robert L. Coleman, Brigitte E. Miller, Peter G. Rose, Heather A. Lankes. (2011) Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study. Gynecologic Oncology 121:2, 303-308
CrossRef43
Simone Marnitz, Christhardt Köhler, Elena Burova, Waldemar Wlodarczyk, Ulrich Jahn, Arne Grün, Volker Budach, Carmen Stromberger. (2011) Helical Tomotherapy with Simultaneous Integrated Boost After Laparoscopic Staging in Patients with Cervical Cancer: Analysis of Feasibility and Early Toxicity. International Journal of Radiation Oncology*Biology*Physics
CrossRef44
Gunjal Garg, Jay P. Shah, Eugene P. Toy, Jayson B. Field, Christopher S. Bryant, J. Rebecca Liu, Robert T. Morris. (2011) Intra-operative detection of nodal metastasis in early stage cervical cancer: A survey of the practice patterns of SGO members. Gynecologic Oncology 121:1, 143-147
CrossRef45
Silvia Biagini, Antonio Bianchi, Tarita Biver, Alessia Boggioni, Igor V. Nikolayenko, Fernando Secco, Marcella Venturini. (2011) DNA binding of a proflavine derivative bearing a platinum hanging residue. Journal of Inorganic Biochemistry 105:4, 558-562
CrossRef46
Kate A. McLean, Weiya Zhang, Rebecca F. Dunsmoor-Su, Chirag A. Shah, Heidi J. Gray, Ron E. Swensen, Barbara A. Goff. (2011) Pelvic exenteration in the age of modern chemoradiation. Gynecologic Oncology 121:1, 131-134
CrossRef47
Rebecca McCaffrey, Mert Bahtiyar, Ernest I. Kohorn, Joseph T. Chambers, Peter E. Schwartz, Setsuko K. Chambers. (2011) Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer. International Journal of Gynecological Cancer 21:3, 535-544
CrossRef48
Pierre Lèguevaque, Stéphanie Motton, Martine Delannes, Denis Querleu, Marc Soulé-Tholy, Gerard Tap, Gilles Houvenaeghel. (2011) Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer?. European Journal of Obstetrics & Gynecology and Reproductive Biology 155:2, 188-192
CrossRef49
SungHwan Cho, Senthilkumar Cinghu, Jae-Ran Yu, Woo-Yoon Park. (2011) Helicase-like transcription factor confers radiation resistance in cervical cancer through enhancing the DNA damage repair capacity. Journal of Cancer Research and Clinical Oncology 137:4, 629-637
CrossRef50
Sarah M. McGuire, Yusuf Menda, Laura L. Boles Ponto, Brandie Gross, Malik Juweid, John E. Bayouth. (2011) A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiotherapy and Oncology 99:1, 49-54
CrossRef51
Tamer Refaat, Amr Elsaid, Nashaat Lotfy, Krystyna Kiel, William Small, Phillip Nickers, Eric Lartigau. (2011) Concomitant chemoradiotherapy with high dose rate brachytherapy as a definitive treatment modality for locally advanced cervical cancer. Alexandria Journal of Medicine 47:1, 15-24
CrossRef52
Xin Lei, Cheng-Yuan Qian, Yi Qing, Ke-Wei Zhao, Zheng-Zhou Yang, Nan Dai, Zhao-Yang Zhong, Cheng Tang, Zheng Li, Xian-Qing Gu, Qian Zhou, Yan Feng, Yan-Li Xiong, Jin-Lu Shan, Dong Wang. (2011) Californium-252 Brachytherapy Combined with External-Beam Radiotherapy for Cervical Cancer: Long-Term Treatment Results. International Journal of Radiation Oncology*Biology*Physics
CrossRef53
Petra Biewenga, Jacobus van der Velden, Ben Willem J. Mol, Lukas J. A. Stalpers, Marten S. Schilthuis, Jan Willem van der Steeg, Matthé P. M. Burger, Marrije R. Buist. (2011) Prognostic model for survival in patients with early stage cervical cancer. Cancer 117:4, 768-776
CrossRef54
J. M. Watkins, P. L. Kearney, K. J. Opfermann, S. J. Ackerman, J. M. Jenrette, M. F. Kohler. (2011) Ultrasound-guided tandem placement for low-dose-rate brachytherapy in advanced cervical cancer minimizes risk of intraoperative uterine perforation. Ultrasound in Obstetrics & Gynecology 37:2, 241-244
CrossRef55
Amol J. Ghia, Victor J. Gonzalez, Jonathan D. Tward, Antoinette M. Stroup, Lisa Pappas, David K. Gaffney. (2011) Primary Vaginal Cancer and Chemoradiotherapy. International Journal of Gynecological Cancer 21:2, 378-384
CrossRef56
Ann H. Klopp, Patricia J. Eifel. (2011) Chemoradiotherapy for Cervical Cancer in 2010. Current Oncology Reports 13:1, 77-85
CrossRef57
JianHua Gan, Jia Sheng, Zhen Huang. (2011) Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery. Science China Chemistry 54:1, 3-23
CrossRef58
Hannah M. Simonds, Jason D. Wright, Naomi du Toit, Alfred I. Neugut, Judith S. Jacobson. (2011) Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa. Cancern/a-n/a
CrossRef59
Raymond H. Mak, Lia M. Halasz, Cynthia K. Tanaka, Marek Ancukiewicz, Delray J. Schultz, Anthony H. Russell, Akila N. Viswanathan. (2011) Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3–4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecologic Oncology 120:1, 101-107
CrossRef60
Seiji Mabuchi, Tadashi Kimura. (2011) Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer. Chemotherapy Research and Practice 2011, 1-10
CrossRef61
Smith Apisarnthanarax, Nirav Dhruva, Farhad Ardeshirpour, Joel E. Tepper, Carol G. Shores, Julian G. Rosenman, William W. Shockley, Michele C. Hayward, D. Neil Hayes. (2011) Concomitant Radiotherapy and Chemotherapy for High-Risk Nonmelanoma Skin Carcinomas of the Head and Neck. International Journal of Surgical Oncology 2011, 1-8
CrossRef62
Na Wang, Quan-Lin Guan, Kai Wang, Xin Zhou, Chen Gao, Han-Teng Yang, Tian-Gen Ni. (2011) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Archives of Gynecology and Obstetrics 283:1, 103-108
CrossRef63
Hun Soon Jung, Ozgur Cem Erkin, Mi Jeong Kwon, Seok Hyung Kim, Jae In Jung, Yu-Kyoung Oh, Song Wook Her, Woong Ju, Yoon-La Choi, Sang Yong Song, Joong Kyu Kim, Young Deug Kim, Ga Yong Shim, Young Kee Shin. (2011) The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. International Journal of Cancern/a-n/a
CrossRef64
Tatsuya Nakamura, Nobukazu Fuwa, Kanako Takayama, Haruo Inokuchi, Takuya Tomoda, Akinori Takada, Chiyoko Makita, Miho Shiomi, Jun-ichi Yokouchi, Kazuo Watanabe. (2011) Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer. Head & Neckn/a-n/a
CrossRef65
Albert J. Chang, Susan Richardson, Perry W. Grigsby, Julie K. Schwarz. (2010) Split-Field Helical Tomotherapy With or Without Chemotherapy for Definitive Treatment of Cervical Cancer. International Journal of Radiation OncologyBiologyPhysics
CrossRef66
K. Yoshikiyo, K. Kratz, K. Hirota, K. Nishihara, M. Takata, H. Kurumizaka, S. Horimoto, S. Takeda, J. Jiricny. (2010) KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents. Proceedings of the National Academy of Sciences 107:50, 21553-21557
CrossRef67
Leslie M. Randall, Bradley J. Monk, James Moon, Ricardo Parker, Muthana Al-Ghazi, Sharon Wilczynski, John P. Fruehauf, Maurie Markman, Robert A. Burger. (2010) Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group Study. Gynecologic Oncology 119:3, 417-421
CrossRef68
G. Ferrandina, P.A. Margariti, D. Smaniotto, M. Petrillo, M.G. Salerno, A. Fagotti, G. Macchia, A.G. Morganti, N. Cellini, G. Scambia. (2010) Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecologic Oncology 119:3, 404-410
CrossRef69
Gabriella Macchia, Gabriella Ferrandina, Francesco Legge, Francesco Deodato, Valeria Ruggieri, Domenica Lorusso, Gilbert D. A. Padula, Vincenzo Valentini, Numa Cellini, Giovanni Scambia, Alessio G. Morganti. (2010) Prolonged Chemoradiation in Locally Advanced Carcinoma of the Uterine Cervix. American Journal of Clinical Oncology 33:6, 577-582
CrossRef70
Cheryl Crozier, Beth Erickson-Wittmann, Benjamin Movsas, Jean Owen, Najma Khalid, J. Frank Wilson. (2010) Shifting the Focus to Practice Quality Improvement in Radiation Oncology. Journal for Healthcare Qualityno-no
CrossRef71
Ryan C. Todd, Stephen J. Lippard. (2010) Consequences of Cisplatin Binding on Nucleosome Structure and Dynamics. Chemistry & Biology 17:12, 1334-1343
CrossRef72
Chel Hun Choi, Yoo-Young Lee, Min Kyu Kim, Tae-Joong Kim, Jeong-Won Lee, Hee Rim Nam, Seung Jae Huh, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim. (2010) A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer. International Journal of Radiation OncologyBiologyPhysics
CrossRef73
Yun Liang, Karen Messer, Brent S. Rose, John H. Lewis, Steve B. Jiang, Catheryn M. Yashar, Arno J. Mundt, Loren K. Mell. (2010) Impact of Bone Marrow Radiation Dose on Acute Hematologic Toxicity in Cervical Cancer: Principal Component Analysis on High Dimensional Data. International Journal of Radiation Oncology*Biology*Physics 78:3, 912-919
CrossRef74
Mei-Qin Zhang, Su-Ping Liu, Xiang-E. Wang. (2010) Concurrent Chemoradiotherapy With Paclitaxel and Nedaplatin Followed by Consolidation Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix: Preliminary Results of a Phase II Study. International Journal of Radiation Oncology*Biology*Physics 78:3, 821-827
CrossRef75
Hee Seung Kim, Ju Yeong Kim, Noh Hyun Park, Kidong Kim, Hyun Hoon Chung, Yong Beom Kim, Jae Weon Kim, Hak Jae Kim, Yong Sang Song, Soon-Beom Kang. (2010) Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer. Gynecologic Oncology 119:2, 217-224
CrossRef76
Elesyia D. Haynes-Outlaw, Perry W. Grigsby. (2010) The Role of FDG-PET/CT in Cervical Cancer: Diagnosis, Staging, Radiation Treatment Planning and Follow-Up. PET Clinics 5:4, 435-446
CrossRef77
Shigeki Takeshita, Tsunekazu Kita, Yoshiyuki Motoike, Koichi Umezawa, Soichi Sugisaki, Sachiyo Matsumoto, Yasuhiro Matsumoto, Eiji Ryo, Takuya Ayabe. (2010) Postoperative concurrent chemoradiotherapy for the high-risk uterine cervical cancer. Journal of Obstetrics and Gynaecology Research 36:5, 1009-1014
CrossRef78
Simone Marnitz, Carmen Stromberger, Michael Kawgan-Kagan, Waldemar Wlodarczyk, Ulrich Jahn, Achim Schneider, Uwe Ulrich, Volker Budach, Christhardt Köhler. (2010) Helical Tomotherapy in Cervical Cancer Patients. Strahlentherapie und Onkologie 186:10, 572-579
CrossRef79
Heather E. Newlin, Robert J. Amdur, Charles E. Riggs, Christopher G. Morris, Jessica M. Kirwan, William M. Mendenhall. (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:19, 4533-4540
CrossRef80
Gunjal Garg, Jay P. Shah, J. Rebecca Liu. (2010) Should Radical Hysterectomy Be Aborted on Intraoperative Detection of Nodal Tumor Metastasis in Early Stage Cervical Cancer?. Journal of Lower Genital Tract Disease 14:4, 374-381
CrossRef81
Nicoletta Colombo, Michele Peiretti. (2010) Critical Review of Neoadjuvant Chemotherapy Followed by Surgery for Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer 20, S47-S48
CrossRef82
Charles Kunos, Shamshad Ali, Fadi W. Abdul-Karim, Frederick B. Stehman, Steven Waggoner. (2010) Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology 203:4, 351.e1-351.e8
CrossRef83
Mark H Einstein, Rébécca Phaëton. (2010) Issues in cervical cancer incidence and treatment in HIV. Current Opinion in Oncology 22:5, 449-455
CrossRef84
C.L. Vale, J.F. Tierney, S.E. Davidson, K.J. Drinkwater, P. Symonds. (2010) Substantial Improvement in UK Cervical Cancer Survival with Chemoradiotherapy: Results of a Royal College of Radiologists’ Audit. Clinical Oncology 22:7, 590-601
CrossRef85
Zeina Al-Mansour, Claire Verschraegen. (2010) Locally advanced cervical cancer: what is the standard of care?. Current Opinion in Oncology 22:5, 503-512
CrossRef86
Rajiv Samant, Sofya Kobeleva, Choan E, Khalid Balaraj, Tien Le, Michael Fung-Kee-Fung. (2010) Evaluating Contemporary Radiotherapy Approaches in the Primary Treatment of Cervical Cancer. International Journal of Gynecological Cancer 20:6, 1087-1091
CrossRef87
V. LOIZZI, G. CORMIO, L. SELVAGGI, C. CARRIERO, G. PUTIGNANO. (2010) Locally advanced cervical cancer associated with complete uterine prolapse. European Journal of Cancer Care 19:4, 548-550
CrossRef88
Shingo Kato, Tatsuya Ohno, Kullathorn Thephamongkhol, Yaowalak Chansilpa, Yang Yuxing, C.R. Beena Devi, Anita Z. Bustam, Miriam J.C. Calaguas, Rey H. de los Reyes, Chul-Koo Cho, To Anh Dung, Nana Supriana, Hideyuki Mizuno, Takashi Nakano, Hirohiko Tsujii. (2010) Multi-Institutional Phase II Clinical Study of Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer in East and Southeast Asia. International Journal of Radiation Oncology*Biology*Physics 77:3, 751-757
CrossRef89
Elizabeth A. Kidd, Barry A. Siegel, Farrokh Dehdashti, Janet S. Rader, Sasa Mutic, David G. Mutch, Matthew A. Powell, Perry W. Grigsby. (2010) Clinical Outcomes of Definitive Intensity-Modulated Radiation Therapy With Fluorodeoxyglucose–Positron Emission Tomography Simulation in Patients With Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 77:4, 1085-1091
CrossRef90
Wee Han Ang, MyatNoeZin Myint, Stephen J. Lippard. (2010) Transcription Inhibition by Platinum−DNA Cross-Links in Live Mammalian Cells. Journal of the American Chemical Society 132:21, 7429-7435
CrossRef91
Ram EITAN, Hanoch LEVAVI, Yoav PELED, Ronen BRENNER, Gad SABAH, Alon BEN-ARIE, Ram DGANI, Ami FISHMAN, Aaron SULKES, Eyal FENIG, Claude KOREN. (2010) Should simple hysterectomy be added after chemo-radiation for stage IB2 and bulky IIA cervical carcinoma?. Australian and New Zealand Journal of Obstetrics and Gynaecology 50:3, 289-293
CrossRef92
Katsunori Kashima, Tetsuro Yahata, Kazuyuki Fujita, Kenichi Tanaka. (2010) Analysis of the complications after radical hysterectomy for stage IB, IIA and IIB uterine cervical cancer patients. Journal of Obstetrics and Gynaecology Research 36:3, 555-559
CrossRef93
Maaike A. van der Aa, Th. J. M. Helmerhorst, Sabine Siesling, Sietske Riemersma, Jan Willem Coebergh. (2010) Vaginal and (Uncommon) Cervical Cancers in the Netherlands, 1989-2003. International Journal of Gynecological Cancer 20:4, 638-645
CrossRef94
Krishnansu S. Tewari, J. Tate Thigpen. (2010) Debate: Cisplatin Plus Paclitaxel in the Treatment of Patients With Metastatic/Recurrent Cervical Cancer. Clinical Ovarian Cancer 3:1, 14-20
CrossRef95
M. Fabbro, L. Gladieff, F. Guichard, M. El Demery, F. Dalenc, C. Kerr, M. Delannes, D. Paraiso, E. Pujade-Lauraine, J.-E. Kurtz. (2010) Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial. Gynecologic Oncology 117:2, 276-280
CrossRef96
Taisuke Mori, Kenichi Hosokawa, Morio Sawada, Haruo Kuroboshi, Hiroshi Tatsumi, Hisato Koshiba, Tomoharu Okubo, Jo Kitawaki. (2010) Neoadjuvant Weekly Carboplatin and Paclitaxel Followed by Radical Hysterectomy for Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:4, 611-616
CrossRef97
Maurizio Serati, Stefano Salvatore, Elena Cattoni, Mara Zanirato, Silvia Mauri, Gabriele Siesto, Antonella Cromi, Fabio Ghezzi, Pierfrancesco Bolis. (2010) The Impact of the Loop Electrosurgical Excisional Procedure for Cervical Intraepithelial Lesions on Female Sexual Function. Journal of Sexual Medicine
CrossRef98
E. Lambaudie, F. Narducci, M. Bannier, C. Jauffret, N. Pouget, E. Leblanc, G. Houvenaeghel. (2010) Role of robot-assisted laparoscopy in adjuvant surgery for locally advanced cervical cancer. European Journal of Surgical Oncology (EJSO) 36:4, 409-413
CrossRef99
Duangmani Thanapprapasr, Adisak Nartthanarung, Puchong Likittanasombut, Nathpong Israngura Na Ayudhya, Chuenkamon Charakorn, Umaporn Udomsubpayakul, Thanya Subhadarbandhu, Sarikapan Wilailak. (2010) Bone Metastasis in Cervical Cancer Patients Over a 10-Year Period. International Journal of Gynecological Cancer 20:3, 373-378
CrossRef100
Jonathan Teh, Swee Peng Yap, Ivan Tham, Vijay K. Sethi, Eu Jin Chua, Richard Yeo, Tew Hong Ho, Eng Hseon Tay, Yin Nin Chia, Lay Tin Soh, Hoon Seng Khoo-Tan. (2010) Concurrent Chemoradiotherapy Incorporating High-Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma. International Journal of Gynecological Cancer 20:3, 428-433
CrossRef101
Elizabeth K. Nugent, Ashley S. Case, John T. Hoff, Israel Zighelboim, Lorri L. DeWitt, Kim Trinkhaus, David G. Mutch, Premal H. Thaker, L. Stewart Massad, Janet S. Rader. (2010) Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin dosing and other clinical prognostic factors. Gynecologic Oncology 116:3, 438-441
CrossRef102
Bogdan Torbé, Michał Falco, Andrzej Torbé, Przemysław Ciepiela, Rafał Kurzawa. (2010) Radiotherapy versus radiochemotherapy with cisplatin in treatment of cervical cancer. Medical Oncology 27:1, 1-8
CrossRef103
N. Walji, A.L. Chue, C. Yap, L.J. Rogers, A. El-Modir, K.K. Chan, K. Singh, I.N. Fernando. (2010) Is There a Role for Adjuvant Hysterectomy after Suboptimal Concurrent Chemoradiation in Cervical Carcinoma?. Clinical Oncology 22:2, 140-146
CrossRef104
Alfonso Dueñas-González, Lucely Cetina, Jaime Coronel, Déborah Martínez-Baños. (2010) Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer. Drugs 70:4, 403-432
CrossRef105
Brian D. Kavanagh, Charlie C. Pan, Laura A. Dawson, Shiva K. Das, X. Allen Li, Randall K. Ten Haken, Moyed Miften. (2010) Radiation Dose–Volume Effects in the Stomach and Small Bowel. International Journal of Radiation Oncology*Biology*Physics 76:3, S101-S107
CrossRef106
Nathan Bittner, Gregory S. Merrick, Kent E. Wallner, Wayne M. Butler, Robert Galbreath, Edward Adamovich. (2010) Whole-Pelvis Radiotherapy in Combination With Interstitial Brachytherapy: Does Coverage of the Pelvic Lymph Nodes Improve Treatment Outcome in High-Risk Prostate Cancer?. International Journal of Radiation Oncology*Biology*Physics 76:4, 1078-1084
CrossRef107
Kathleen M. Schmeler, Anuja Jhingran, Revathy B. Iyer, Charlotte C. Sun, Patricia J. Eifel, Pamela T. Soliman, Pedro T. Ramirez, Michael Frumovitz, Diane C. Bodurka, Anil K. Sood. (2010) Pelvic fractures after radiotherapy for cervical cancer. Cancer 116:3, 625-630
CrossRef108
Stéphanie Motton, Gilles Houvenaeghel, Martine Delannes, Denis Querleu, Marc Soulé-Tholy, Jean Hoff, Pierre Lèguevaque. (2010) Results of Surgery After Concurrent Chemoradiotherapy in Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:2, 268-275
CrossRef109
M. Herbolsheimer. (2010) Zu hohe Cisplatin-Dosen bei der simultanen Radiochemotherapie des Zervixkarzinoms?. Der Onkologe 16:2, 187-188
CrossRef110
Jen-Yu Tseng, Ming-Shien Yen, Nae-Fong Twu, Chiung-Ru Lai, Huann-Cheng Horng, Chien-Chih Tseng, Kuan-Chong Chao, Chi-Mou Juang. (2010) Prognostic nomogram for overall survival in stage IIB-IVA cervical cancer patients treated with concurrent chemoradiotherapy. American Journal of Obstetrics and Gynecology 202:2, 174.e1-174.e7
CrossRef111
Martine Franckena, Jacoba van der Zee. (2010) Use of combined radiation and hyperthermia for gynecological cancer. Current Opinion in Obstetrics and Gynecology 22:1, 9-14
CrossRef112
Lara Barazzuol, Neil G. Burnet, Raj Jena, Bleddyn Jones, Sarah J. Jefferies, Norman F. Kirkby. (2010) A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. Journal of Theoretical Biology 262:3, 553-565
CrossRef113
Murat Sonmezer, Kutluk Oktay. (2010) Orthotopic and heterotopic ovarian tissue transplantation. Best Practice & Research Clinical Obstetrics & Gynaecology 24:1, 113-126
CrossRef114
Astrid Baalbergen, Yerney Veenstra, Lukas L Stalpers, Anca C Ansink, Astrid Baalbergen. 2010. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. .
CrossRef115
, Claire L Vale. 2010. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. .
CrossRef116
Rafael Martínez-Monge, Miren Gaztañaga, José Manuel Aramendía, Mauricio Cambeiro, Leire Arbea, Jaime Espinós, José Javier Aristu, Matías Jurado. (2010) A Phase II Trial of Less Than 7 Weeks of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:1, 133-140
CrossRef117
José Pérez-Regadera, Alfonso Sánchez-Muñoz, Javier De-la-Cruz, Claudio Ballestín, David Lora, Rosa García-Martín, Lorenzo Alonso-Carrión, Cesar Mendiola, Eduardo Lanzós. (2010) Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer. International Journal of Gynecological Cancer 20:1, 164-172
CrossRef118
A.P. GREYSTOKE, D.I. JODRELL, M. CHEUNG, I. RIVANS, M.J. MACKEAN. (2010) How many cisplatin administration protocols does your department use?. European Journal of Cancer Care 19:1, 80-90
CrossRef119
Tae Jin Han, Hong-Gyun Wu, Hak Jae Kim, Sung Whan Ha, Soon-Beom Kang, Yong-Sang Song, Noh-Hyun Park. (2010) Effects of Concurrent Chemotherapy and Postoperative Prophylactic Paraaortic Irradiation for Cervical Cancer with Common Iliac Node Involvement. The Journal of the Korean Society for Therapeutic Radiology and Oncology 28:3, 125
CrossRef120
Claudio C. Carmo, Ronir R. Luiz. (2010) Indication of Radiotherapy for Women With Cervical Cancer in Rio De Janeiro, Brazil. International Journal of Gynecological Cancer 20:1, 158-163
CrossRef121
Lilian T. Gien, Marie-Claude Beauchemin, Gillian Thomas. (2010) Adenocarcinoma: A unique cervical cancer. Gynecologic Oncology 116:1, 140-146
CrossRef122
Maxime Fastrez, Jean Vandromme, Pascale George, Serge Rozenberg, Michel Degueldre. (2009) Robot assisted laparoscopic transperitoneal para-aortic lymphadenectomy in the management of advanced cervical carcinoma. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:2, 226-229
CrossRef123
Katrien Vandecasteele, Wilfried Neve, Werner Gersem, Louke Delrue, Leen Paelinck, Amin Makar, Valérie Fonteyne, Carlos Wagter, Geert Villeirs, Gert Meerleer. (2009) Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer. Strahlentherapie und Onkologie 185:12, 799-807
CrossRef124
Fiona J Gilbert, Trevor S Ahearn. (2009) Dynamic contrast-enhanced MRI in cancer. Imaging in Medicine 1:2, 173-186
CrossRef125
Seiji Mabuchi, Ken-ichirou Morishige, Fumiaki Isohashi, Yasuo Yoshioka, Takashi Takeda, Toshiya Yamamoto, Kiyoshi Yoshino, Takayuki Enomoto, Takehiro Inoue, Tadashi Kimura. (2009) Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecologic Oncology 115:3, 482-487
CrossRef126
Jamal Rahaman, Norma Steiner, Monica Prasad Hayes, Linus Chuang, David Fishman, Herbert Gretz III. (2009) Chemotherapy for Gynecologic Cancers. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:6, 577-588
CrossRef127
Daniel H. Kim, Alice Wang-Chesebro, Vivian Weinberg, Jean Pouliot, Lee-May Chen, Joycelyn Speight, Ramey Littell, I.-Chow Hsu. (2009) High–Dose Rate Brachytherapy Using Inverse Planning Simulated Annealing for Locoregionally Advanced Cervical Cancer: A Clinical Report With 2-Year Follow-Up. International Journal of Radiation Oncology*Biology*Physics 75:5, 1329-1334
CrossRef128
Maaike A. van der Aa, Sabine Siesling, Lonneke V. v.d. Poll-Franse, Eltjo M. Schutter, Marnix L. Lybeert, Jan Willem W. Coebergh. (2009) Age-specific differences in the treatment of cervical cancer in the east and the south of The Netherlands 1989–2004. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:1, 78-82
CrossRef129
Heitor Ricardo Cosiski Marana, Jurandyr Moreira de Andrade, Francisco José Cândido dos Reis, Daniel Guimarães Tiezzi, Fábio Eduardo Zola, Willan Simões Clagnan, Alexandre Pavan Garieri. (2009) Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy. Journal of Surgical Oncology 100:6, 505-510
CrossRef130
Yuko Kaneyasu, Nobutaka Nagai, Yasushi Nagata, Yasutoshi Hashimoto, Shintaro Yuki, Yuji Murakami, Masahiro Kenjo, Hideaki Kakizawa, Naoyuki Toyota, Hisaya Fujiwara, Yoshiki Kudo, Katsuhide Ito. (2009) Intra-Arterial Infusion Chemotherapy Using Cisplatin With Radiotherapy for Stage III Squamous Cell Carcinoma of the Cervix. International Journal of Radiation Oncology*Biology*Physics 75:2, 369-377
CrossRef131
Scott I.K. Semple, Vanessa N. Harry, David E. Parkin, Fiona J. Gilbert. (2009) A Combined Pharmacokinetic and Radiologic Assessment of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Predicts Response to Chemoradiation in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 75:2, 611-617
CrossRef132
Maurizio Serati, Stefano Salvatore, Stefano Uccella, Rosa M Laterza, Antonella Cromi, Fabio Ghezzi, Pierfrancesco Bolis. (2009) Sexual Function after Radical Hysterectomy for Early-Stage Cervical Cancer: Is There a Difference between Laparoscopy and Laparotomy?. Journal of Sexual Medicine 6:9, 2516-2522
CrossRef133
Shohreh Nafisi, Zeinab Norouzi. (2009) A Comparative Study on the Interaction of Cis - and Trans -Platin with DNA and RNA. DNA and Cell Biology 28:9, 469-477
CrossRef134
P.E. Colombo, M.M. Bertrand, M. Gutowski, A. Mourregot, M. Fabbro, B. Saint-Aubert, F. Quenet, S. Gourgou, C. Kerr, P. Rouanet. (2009) Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: Surgical morbidity and oncological results. Gynecologic Oncology 114:3, 404-409
CrossRef135
S. Goonatillake, R. Khong, P. Hoskin. (2009) Chemoradiation in Gynaecological Cancer. Clinical Oncology 21:7, 566-572
CrossRef136
Mihály Patyánik, Csaba Nemeskéri, Zsuzsa Póti, Dániel Sinkó, Csilla Pesznyák, Réka Király, Róbert Kois, Árpád Mayer. (2009) Concomitant Radiochemotherapy of Cervical Cancer. Strahlentherapie und Onkologie 185:9, 582-587
CrossRef137
Jennifer M. Tornatta, Janet S. Carpenter, Jeanne Schilder, Higinia R. Cardenes. (2009) Representations of Vaginal Symptoms in Cervical Cancer Survivors. Cancer Nursing 32:5, 378-384
CrossRef138
José Humberto Tavares Guerreiro Fregnani, Maria do Rosário Dias de Oliveira Latorre, Pablo Roberto Novik, Ademar Lopes, Júnea Cáris de Oliveira, Audrey Tieko Tsunoda, Fernando Augusto Soares. (2009) Extent of pelvic lymphadenectomy in women with squamous cell carcinoma of the uterine cervix: Is there any prognostic value?. Journal of Surgical Oncology 100:3, 252-257
CrossRef139
Francesco Fanfani, Anna Fagotti, Gabriella Ferrandina, Francesco Raspagliesi, Antonino Ditto, Anna Maria Cerrotta, Alessio Morganti, Daniela Smaniotto, Giovanni Scambia. (2009) Neoadjuvant Chemoradiation Followed by Radical Hysterectomy in FIGO Stage IIIB Cervical Cancer. International Journal of Gynecological Cancer 19:6, 1119-1124
CrossRef140
Vanessa N. Harry, Fiona J. Gilbert, David E. Parkin. (2009) Predicting the Response of Advanced Cervical and Ovarian Tumors to Therapy. Obstetrical & Gynecological Survey 64:8, 548-560
CrossRef141
Sujana Movva, Lorna Rodriguez, Hugo Arias-Pulido, Claire Verschraegen. (2009) Novel chemotherapy approaches for cervical cancer. Cancer 115:14, 3166-3180
CrossRef142
Takahiro Kasamatsu, Takashi Onda, Morio Sawada, Tomoyasu Kato, Shun-ichi Ikeda. (2009) Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation. Gynecologic Oncology 114:1, 69-74
CrossRef143
K. Shibata, H. Kajiyama, E. Yamamoto, M. Terauchi, K. Ino, S. Nomura, A. Nawa, M. Kawai, F. Kikkawa. (2009) Effectiveness of preoperative concurrent chemoradiation therapy (CCRT) for locally advanced adenocarcinoma of cervix. European Journal of Surgical Oncology (EJSO) 35:7, 768-772
CrossRef144
Kari L. Ring, Jennifer L. Young, Neal E. Dunlap, Willie A. Andersen, Bernard F. Schneider. (2009) Extended-field radiation therapy with whole pelvis radiotherapy and cisplatin chemosensitization in the treatment of IB2-IIIB cervical carcinoma: a retrospective review. American Journal of Obstetrics and Gynecology 201:1, 109.e1-109.e6
CrossRef145
Maurie Markman. (2009) Presentation of Chemotherapy Options for Cervix Cancer on Cancer-Related Internet Sites. Journal of Women's Health 18:6, 827-829
CrossRef146
Yuh-Cheng Yang, K.S. Clifford Chao, Chin-Ping Lin, Yu-Yawn Chen, Kung-Liahng Wang, Yu-Jen Chen. (2009) Oxaliplatin Regulates DNA Repair Responding to Ionizing Radiation and Enhances Radiosensitivity of Human Cervical Cancer Cells. International Journal of Gynecological Cancer 19:4, 782-786
CrossRef147
Kate Parker, Eve Gallop-Evans, Louise Hanna, Malcolm Adams. (2009) Five Years' Experience Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiotherapy and High-Dose-Rate Brachytherapy: Results From a Single Institution. International Journal of Radiation Oncology*Biology*Physics 74:1, 140-146
CrossRef148
Geraldine Jacobson, John Lammli, Gideon Zamba, Lei Hua, Michael J. Goodheart. (2009) Thromboembolic events in patients with cervical carcinoma: Incidence and effect on survival. Gynecologic Oncology 113:2, 240-244
CrossRef149
Kenji Umayahara, Nobuhiro Takeshima, Takayuki Nose, Kiyoshi Fujiwara, Yuko Sugiyama, Kuniko Utsugi, Takashi Yamashita, Ken Takizawa. (2009) Phase I Study of Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel Chemotherapy for Locally Advanced Cervical Carcinoma in Japanese Women. International Journal of Gynecological Cancer 19:4, 723-727
CrossRef150
Rosa De Vincenzo, Giulia Amadio, Caterina Ricci, Angelo Licameli, Gabriella Ferrandina, Giovanni Capelli, Giovanni Scambia. (2009) Treatment of cervical cancer in Italy: Strategies and their impact on the women. Vaccine 27, A39-A45
CrossRef151
Fumiaki Isohashi, Yasuo Yoshioka, Masahiko Koizumi, Koji Konishi, Iori Sumida, Yutaka Takahashi, Toshiyuki Ogata, Ken-ichirou Morishige, Takayuki Enomoto, Yoshifumi Kawaguchi, Tadayuki Kotsuma, Kana Adachi, Shoichi Fukuda, Yuichi Akino, Takehiro Inoue. (2009) High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma. Brachytherapy 8:2, 234-239
CrossRef152
Lisa Barbera, Gillian Thomas. (2009) Management of Early and Locally Advanced Cervical Cancer. Seminars in Oncology 36:2, 155-169
CrossRef153
George A. Plataniotis, Roger G. Dale. (2009) Use of the Concept of Equivalent Biologically Effective Dose (BED) to Quantify the Contribution of Hyperthermia to Local Tumor Control in Radiohyperthermia Cervical Cancer Trials, and Comparison With Radiochemotherapy Results. International Journal of Radiation Oncology*Biology*Physics 73:5, 1538-1544
CrossRef154
R Tozzi, F Lavra, T Cassese, R Garruto Campanile, V Pedicini, M Bignardi, M Scorsetti, A Bertuzzi. (2009) Laparoscopic debulking of bulky lymph nodes in women with cervical cancer: indication and surgical outcomes. BJOG: An International Journal of Obstetrics & Gynaecology 116:5, 688-692
CrossRef155
Viorica Nagy, Ovidiu Coza, Claudia Ordeanu, Alexandru Třailă, Alin Rancea, Nicolae Todor, Nicolae Ghilezan. (2009) Radiotherapy versus Concurrent 5-Day Cisplatin and Radiotherapy in Locally Advanced Cervical Carcinoma. Strahlentherapie und Onkologie 185:3, 177-183
CrossRef156
Behiye P.C. Goksedef, Charles Kunos, Jerome L. Belinson, Peter G. Rose. (2009) Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma. American Journal of Obstetrics and Gynecology 200:2, 175.e1-175.e5
CrossRef157
S. Spensley, R.D. Hunter, J.E. Livsey, R. Swindell, S.E. Davidson. (2009) Clinical Outcome for Chemoradiotherapy in Carcinoma of the Cervix. Clinical Oncology 21:1, 49-55
CrossRef158
Vicente Tormo Ferrero, Francisco J. Andreu Martínez, Rafael Cardenal Maciá. (2009) Evaluation of toxicity of surgery and/or chemoirradiation treatment of uterine cervix cancer. Clinical and Translational Oncology 11:2, 109-113
CrossRef159
Min Kyu Kang, Won Park, Yoon-La Choi, Eun Yoon Cho, Geunghwan Ahn, HeeRim Nam, Seung Jae Huh, Yong Chan Ahn, Do Hoon Lim, Dong Ryul Oh, Duk Soo Bae, Byoung Gie Kim. (2009) The Effect of Cyclooxygenase-2 Expression on Tumor Volume Response in Patients Treated with Radiotherapy for Uterine Cervical Cancer. Journal of Korean Medical Science 24:6, 1170
CrossRef160
Yong Wook Jung, San Hui Lee, Ji Heum Paek, Eun Ji Nam, Sang Wun Kim, Jae Hoon Kim, Jae Wook Kim, Young Tae Kim. (2009) Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer. Journal of Gynecologic Oncology 20:3, 151
CrossRef161
V. Plesinac-Karapandzic, N. Borojevic, B. Markovic, V. Stankovic, S. Vuckovic, S. Plesinac. (2009) Implementation of 3D-CT based brachytherapy in the postoperative radiotherapy of cervical cancer: Treatment technique and dose-volume parameters. Acta chirurgica iugoslavica 56:4, 201-207
CrossRef162
Eui-Sok Sol, Tae Sung Lee, Suk Bong Koh, Hun Kyu Oh, Gi Won Ye, Youn Seok Choi. (2009) Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma. Journal of Gynecologic Oncology 20:1, 28
CrossRef163
David K. Gaffney, Andreas Du Bois, Kailash Narayan, Nick Reed, Takafumi Toita, Sandro Pignata, Peter Blake, Lorraine Portelance, Azmat Sadoyze, Richard Potter, Alessandro Colombo, Marcus Randall, Mansoor R. Mirza, Edward L. Trimble. (2009) Patterns of Care for Radiotherapy in Vulvar Cancer. International Journal of Gynecological Cancer 19:1, 163-167
CrossRef164
Ryan C. Todd, Stephen J. Lippard. (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1:4, 280
CrossRef165
Jae Myoung Noh, Won Park, Seung Jae Huh, Eun Yoon Cho, Yoon-La Choi, Je Ho Lee, Duk Soo Bae. (2009) Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma. Journal of Gynecologic Oncology 20:4, 215
CrossRef166
V. Plesinac-Karapandzic, N. Borojevic, Z. Milosevic, B. Markovic, M. Nikitovic, S. Plesinac. (2009) Postoperative radiotherapy of cervival carcinoma: Treatment results and analysis of prognostic factors. Acta chirurgica iugoslavica 56:4, 195-200
CrossRef167
Kathleen McIntyre-Seltman, Jamie L. Lesnock. (2008) Cervical Cancer Screening in Pregnancy. Obstetrics and Gynecology Clinics of North America 35:4, 645-658
CrossRef168
Florence Huguet, Oana-Maria Cojocariu, Pierre Levy, Jean-Pierre Lefranc, Emile Darai, Denis Jannet, Yan Ansquer, Pierre-Eugène Lhuillier, Jean-Louis Benifla, Nathalie Seince, Emmanuel Touboul. (2008) Preoperative Concurrent Radiation Therapy and Chemotherapy for Bulky Stage IB2, IIA, and IIB Carcinoma of the Uterine Cervix With Proximal Parametrial Invasion. International Journal of Radiation Oncology*Biology*Physics 72:5, 1508-1515
CrossRef169
S van Dyk, D Byram, D Bernshaw. (2008) Brachytherapy for cancer of the cervix: An Australian and New Zealand survey of current treatment techniques. Journal of Medical Imaging and Radiation Oncology 52:6, 588-597
CrossRef170
George A. Plataniotis, Roger G. Dale. (2008) Use of Concept of Chemotherapy-Equivalent Biologically Effective Dose to Provide Quantitative Evaluation of Contribution of Chemotherapy to Local Tumor Control in Chemoradiotherapy Cervical Cancer Trials. International Journal of Radiation Oncology*Biology*Physics 72:5, 1538-1543
CrossRef171
Claudio C. Carmo, Ronir R. Luiz, Gustavo Silva. (2008) The effect of addition of chemotherapy to radiotherapy in the treatment of women with cervical cancer: A survival analysis using propensity score. Gynecologic Oncology 111:2, 271-275
CrossRef172
Ji-An Liang, Shang-Wen Chen, Wei-Chun Chang, Yao-Ching Hung, Lian-Shung Yeh, Shih-Neng Yang, Fang-Jen Lin. (2008) Risk Stratification for Failure in Patients with Advanced Cervical Cancer after Concurrent Chemoradiotherapy: Another Way to Optimise Treatment Results. Clinical Oncology 20:9, 683-690
CrossRef173
Rozilawati Ahmad, Mischa S. Hoogeman, Sandra Quint, Jan Willem Mens, Ilse de Pree, Ben J.M. Heijmen. (2008) Inter-fraction bladder filling variations and time trends for cervical cancer patients assessed with a portable 3-dimensional ultrasound bladder scanner. Radiotherapy and Oncology 89:2, 172-179
CrossRef174
Oliver Zivanovic, Kaled M. Alektiar, Yukio Sonoda, Qin Zhou, Alexia Iasonos, William P. Tew, John P. Diaz, Dennis S. Chi, Richard R. Barakat, Nadeem R. Abu-Rustum. (2008) Treatment patterns of FIGO Stage IB2 cervical cancer: A single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecologic Oncology 111:2, 265-270
CrossRef175
J. PETSUKSIRI, Y. CHANSILPA, S. THERASAKVICHYA, N. SUNTORNPONG, K. THEPHAMONGKHOL, P. DANKULCHAI, P. MAHASITTHIWAT, N. IEUMWANANONTHACHAI, V. VEERASARN, S. SANGRUCHI, P. PATTARANUTAPORN. (2008) Treatment options in bulky stage IB cervical carcinoma. International Journal of Gynecological Cancer 18:6, 1153-1162
CrossRef176
T Ota, N Takeshima, T Tabata, K Hasumi, K Takizawa. (2008) Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. British Journal of Cancer 99:8, 1216-1220
CrossRef177
George A. Omura. (2008) Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience. Seminars in Oncology 35:5, 507-521
CrossRef178
J. KODAMA, M. TAKEMOTO, N. SEKI, K. NAKAMURA, A. HONGO, S. KANAZAWA, Y. HIRAMATSU. (2008) Phase I study of weekly nedaplatin and concurrent pelvic radiotherapy as adjuvant therapy after radical surgery for cervical cancer. International Journal of Gynecological Cancer 18:5, 1037-1041
CrossRef179
M. CAIRNS, V. HARRY, T.K. SARKAR, D.E. PARKIN. (2008) Treatment of advanced cervical cancer: a population-based study. European Journal of Cancer Care
CrossRef180
Lucía González-Cortijo, N. Carballo, A. González-Martín, V. Corraliza, L. Chiva de Agustín, F. Lapuente Sastre, J.F. García García, A. Rojo Sebastián, J. Hornedo, R. Colomer. (2008) Novel chemotherapy approaches in chemoradiation protocols. Gynecologic Oncology 110:3, S45-S48
CrossRef181
N. Carballo, L. González-Cortijo, A. González-Martín, A. Rojo, L. Chiva. (2008) Indications for adjuvant radiotherapy treatment after surgery and novel modalities for treatment. Gynecologic Oncology 110:3, S41-S44
CrossRef182
Edward L. Trimble, Linda C. Harlan, David Gius, Jennifer Stevens, Stephen M. Schwartz. (2008) Patterns of care for women with cervical cancer in the United States. Cancer 113:4, 743-749
CrossRef183
Tsuguhisa Nashiro, Chiaki Yagi, Makoto Hirakawa, Morihiko Inamine, Yutaka Nagai, Kaoru Sakumoto, Wakana Tamaki, Kazuhiko Ogawa, Takafumi Toita, Yoichi Aoki. (2008) Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. International Journal of Clinical Oncology 13:4, 335-339
CrossRef184
J.F. Tierney, C. Vale, P. Symonds. (2008) Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer. Clinical Oncology 20:6, 401-416
CrossRef185
Loren K. Mell, Hanifi Tiryaki, Kang-Hyun Ahn, Arno J. Mundt, John C. Roeske, Bulent Aydogan. (2008) Dosimetric Comparison of Bone Marrow-Sparing Intensity-Modulated Radiotherapy Versus Conventional Techniques for Treatment of Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 71:5, 1504-1510
CrossRef186
Karen K. Lo, Anne O. Rodriguez, Janice Ryu, Vijay P. Khatri. (2008) Current management of stage IB2 and bulky IIA, locally advanced, and recurrent cervical carcinoma. Oncology Reviews 2:2, 117-128
CrossRef187
Magnus Jensen, Willy Nerdal. (2008) Anticancer cisplatin interactions with bilayers of total lipid extract from pig brain: A 13C, 31P and 15N solid-state NMR study. European Journal of Pharmaceutical Sciences 34:2-3, 140-148
CrossRef188
C.J. DARUS, M.B. CALLAHAN, Q.-N. NGUYEN, L.M. PASTORE, B.F. SCHNEIDER, L.W. RICE, A.A. JAZAERI. (2008) Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. International Journal of Gynecological Cancer 18:4, 730-735
CrossRef189
Numa Cellini, Daniela Smaniotto, Giovanni Scambia, Stefano Luzi, Mario Balducci, Gabriella Ferrandina, Barbara Corvari, Pasquale A. Margariti, Vincenzo Valentini, Giuseppe DʼAgostino. (2008) Chemoradiation With Concomitant Boost Followed by Radical Surgery in Locally Advanced Cervical Cancer: A Dose-Escalation Study. American Journal of Clinical Oncology 31:3, 280-284
CrossRef190
Jergin Chen, O Kenneth Macdonald, David K. Gaffney. (2008) Incidence, Mortality, and Prognostic Factors of Small Cell Carcinoma of the Cervix. Obstetrics & Gynecology 111:6, 1394-1402
CrossRef191
X. Carcopino, G. Houvenaeghel, M. Buttarelli, B. Esterni, A. Tallet, A. Goncalves, J. Jacquemier. (2008) Equivalent survival in patients with advanced stage IB–II and III–IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy. European Journal of Surgical Oncology (EJSO) 34:5, 569-575
CrossRef192
Chel Hun Choi, Heeseok Kang, Woo Young Kim, Tae-Joong Kim, Jeong-Won Lee, Seung Jae Huh, Je-Ho Lee, Byoung-Gie Kim, Duk-Soo Bae. (2008) Prognostic Value of Baseline Lymphocyte Count in Cervical Carcinoma Treated With Concurrent Chemoradiation. International Journal of Radiation Oncology*Biology*Physics 71:1, 199-204
CrossRef193
F. J. P. Hoebers, D. Pluim, A. A. M. Hart, M. Verheij, A. J. M. Balm, G. Fons, C. R. N. Rasch, J. H. M. Schellens, L. J. A. Stalpers, H. Bartelink, A. C. Begg. (2008) Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemotherapy and Pharmacology 61:6, 1075-1081
CrossRef194
Scott D. Richard, Thomas C. Krivak, Anthony Castleberry, Sushil Beriwal, Joseph L. Kelley, Robert P. Edwards, Paniti Sukumvanich. (2008) Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecologic Oncology 109:1, 43-48
CrossRef195
Bradford P. Whitcomb. (2008) Gynecologic Malignancies. Surgical Clinics of North America 88:2, 301-317
CrossRef196
Denis Querleu, Gwenael Ferron, Arash Rafii, Emilie Bouissou, Martine Delannes, Eliane Mery, Laurence Gladieff. (2008) Pelvic lymph node dissection via a lateral extraperitoneal approach: Description of a technique. Gynecologic Oncology 109:1, 81-85
CrossRef197
Andrea K. Ng, Lois B. Travis. (2008) Second Primary Cancers: An Overview. Hematology/Oncology Clinics of North America 22:2, 271-289
CrossRef198
James E. Kendrick, J. Michael Straughn, Patsy G. Oliver, Wenquan Wang, Li Nan, William E. Grizzle, Cecil R. Stockard, Ronald D. Alvarez, Donald J. Buchsbaum. (2008) Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecologic Oncology 108:3, 591-597
CrossRef199
J.A. LACHANCE, C.J. DARUS, G.J. STUKENBORG, B.F. SCHNEIDER, L.W. RICE, A.A. JAZAERI. (2008) A cost comparison of two strategies for treating stage IB2 cervical cancer. International Journal of Gynecological Cancer 18:2, 274-278
CrossRef200
Martine Franckena, Lukas J.A. Stalpers, Peter C.M. Koper, Ruud G.J. Wiggenraad, Wim J. Hoogenraad, Jan D.P. van Dijk, Carla C. Wárlám-Rodenhuis, Jan J. Jobsen, Gerard C. van Rhoon, Jacoba van der Zee. (2008) Long-Term Improvement in Treatment Outcome After Radiotherapy and Hyperthermia in Locoregionally Advanced Cervix Cancer: An Update of the Dutch Deep Hyperthermia Trial. International Journal of Radiation Oncology*Biology*Physics 70:4, 1176-1182
CrossRef201
T. UNO, A. MITSUHASHI, K. ISOBE, S. YAMAMOTO, H. KAWAKAMI, N. UENO, H. USUI, S. TATE, T. KAWATA, H. ITO. (2008) Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. International Journal of Gynecological Cancer 18:1, 80-84
CrossRef202
Lisa Barbera, Gillian Thomas. (2008) Venous thromboembolism in cervical cancer. The Lancet Oncology 9:1, 54-60
CrossRef203
Young Seok Kim, Seong Soo Shin, Joo-Hyun Nam, Young-Tak Kim, Yong-Man Kim, Jong Hoon Kim, Eun Kyung Choi. (2008) Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecologic Oncology 108:1, 195-200
CrossRef204
Young Seok Seo, Chul Koo Cho, Seong Yul Yoo, Mi Sook Kim, Kang Mo Yang, Hyung Jun Yoo, Chul Won Choi, Kyung Hee Lee, Eui Don Lee, Sang Young Rhu, Suck Chul Choi, Moon Hong Kim, Beob Jong Kim. (2008) Accelerated Hyperfractionated Radiotherapy for Locally Advanced Uterine Cervix Cancers. The Journal of the Korean Society for Therapeutic Radiology and Oncology 26:1, 24
CrossRef205
Il Jung Choi, Moon Seok Cha, Eunku Seul Park, Myung Seok Han, Youngmin Choi, Goo Hwa Je, Hyun Ho Kim. (2008) The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. Journal of Gynecologic Oncology 19:2, 129
CrossRef206
Gabriella Ferrandina, Francesco Fanfani, Manuela Ludovisi, Anna Fagotti, Arnaldo Carbone, Gianfranco Zannoni, Massimiliano Guerriero, Marco Petrillo, Giovanni Scambia. (2008) Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?. Gynecologic Oncology 108:1, 220-225
CrossRef207
A. Goncalves, M. Fabbro, C. Lhommé, L. Gladieff, J.-M. Extra, A. Floquet, L. Chaigneau, A. Tisseron Carrasco, P. Viens. (2008) A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology 108:1, 42-46
CrossRef208
T. MORI, K. HOSOKAWA, Y. KINOSHITA, A. WATANABE, H. HONJO. (2008) Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma. International Journal of Gynecological Cancer 18:1, 85-89
CrossRef209
M. GOODHEART, G. JACOBSON, B.J. SMITH, L. ZHOU. (2008) Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity. International Journal of Gynecological Cancer 18:1, 95-103
CrossRef210
Makoto Hirakawa, Yutaka Nagai, Morihiko Inamine, Kazuya Kamiyama, Kazuhiko Ogawa, Takafumi Toita, Sadayuki Murayama, Yoichi Aoki. (2008) Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecologic Oncology 108:1, 126-129
CrossRef211
Sang Yoon Park, Duk-Soo Bae, Joo Hyun Nam, Chong Taik Park, Chi-Heum Cho, Jong Min Lee, Myung Kyung Lee, Soo Hyun Kim, Sang Min Park, Young Ho Yun. (2007) Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 110:12, 2716-2725
CrossRef212
Elizabeth L. Jewell, Shalini Kulasingam, Evan R. Myers, Angeles Alvarez Secord, Laura J. Havrilesky. (2007) Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: A cost effectiveness analysis. Gynecologic Oncology 107:3, 532-540
CrossRef213
Thumwadee Tangsiriwatthana, Bandit Chumworathayi, Pissamai Yuenyao, Sanguanchoke Luanratanakorn, Jeerichuda Pattamadilok. (2007) Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer. Radiation Medicine 25:10, 502-510
CrossRef214
Renaud de Crevoisier, Nicholas Sanfilippo, Alain Gerbaulet, Philippe Morice, Christophe Pomel, Damiene Castaigne, Patricia Pautier, Catherine Lhomme, Pierre Duvillard, Christine Haie-meder. (2007) Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiotherapy and Oncology 85:3, 362-370
CrossRef215
Bandit Chumworathayi, Pissamai Yuenyao, Vorachai Tangvorapongchai, Sanguanchoke Luanratanakorn, Jeerichuda Pattamadilok, Srichai Krusun. (2007) Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women. Radiation Medicine 25:9, 474-479
CrossRef216
S. ACKERMANN, M. W. BECKMANN, F. THIEL, T. BOGENRIEDER. (2007) Topotecan in cervical cancer. International Journal of Gynecological Cancer 17:6, 1215-1223
CrossRef217
Peter G. Rose. (2007) The flower looks as good as its bud. American Journal of Obstetrics and Gynecology 197:5, 443-444
CrossRef218
Frederick B. Stehman, Shamshad Ali, Henry M. Keys, Laila I. Muderspach, Weldon E. Chafe, Donald G. Gallup, Joan L. Walker, Deborah Gersell. (2007) Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. American Journal of Obstetrics and Gynecology 197:5, 503.e1-503.e6
CrossRef219
T Ota, N Takeshima, T Tabata, K Hasumi, K Takizawa. (2007) Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers. British Journal of Cancer 97:8, 1058-1062
CrossRef220
Michelle L. Harrison, Thomas Ind, Peter Blake, Martin E. Gore. 2007. Multidisciplinary Team Management of Gynaecological Cancers. .
CrossRef221
G. Ferrandina, F. Legge, A. Fagotti, F. Fanfani, M. Distefano, A. Morganti, N. Cellini, G. Scambia. (2007) Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: Safety, outcome, and prognostic measures. Gynecologic Oncology 107:1, S127-S132
CrossRef222
Kung-Liahng Wang, Yuh-Cheng Yang, K. S. Clifford Chao, Meng-Hao Wu, Hung-Chi Tai, Tze-Chien Chen, Ming-Chao Huang, Jen-Ruei Chen, Tsung-Hsien Su, Yu-Jen Chen. (2007) Correlation of Traditional Point a With Anatomic Location of Uterine Artery and Ureter in Cancer of the Uterine Cervix. International Journal of Radiation Oncology*Biology*Physics 69:2, 498-503
CrossRef223
Isabelle Cadron, Toon Van Gorp, Frederic Amant, Karin Leunen, Patrick Neven, Ignace Vergote. (2007) Chemotherapy for recurrent cervical cancer. Gynecologic Oncology 107:1, S113-S118
CrossRef224
Pierluigi Benedetti Panici, Filippo Bellati, Natalina Manci, Milena Pernice, Francesco Plotti, Violante Di Donato, Marco Calcagno, Marzio Angelo Zullo, Ludovico Muzii, Roberto Angioli. (2007) Neoadjuvant Chemotherapy Followed by Radical Surgery in Patients Affected by FIGO Stage IVA Cervical Cancer. Annals of Surgical Oncology 14:9, 2643-2648
CrossRef225
Kutluk Oktay, Murat S??nmezer. (2007) Fertility preservation in gynecologic cancers. Current Opinion in Oncology 19:5, 506-511
CrossRef226
Kathleen N. Moore, Michael A. Gold, D. Scott McMeekin, Kristin K. Zorn. (2007) Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecologic Oncology 106:3, 498-501
CrossRef227
David K. Gaffney, Kathryn Winter, Adam P. Dicker, Brigitte Miller, Patricia J. Eifel, Janice Ryu, Vilija Avizonis, Mitch Fromm, William Small, Kathryn Greven. (2007) Efficacy and Patterns of Failure for Locally Advanced Cancer of the Cervix Treated With Celebrex (Celecoxib) and Chemoradiotherapy in RTOG 0128. International Journal of Radiation Oncology*Biology*Physics 69:1, 111-117
CrossRef228
Jonas van de Lande, Bas Torrenga, Pieter G.H.M. Raijmakers, Otto S. Hoekstra, Marchien W. van Baal, Hans A.M. Brölmann, René H.M. Verheijen. (2007) Sentinel lymph node detection in early stage uterine cervix carcinoma: A systematic review. Gynecologic Oncology 106:3, 604-613
CrossRef229
Robert Higgins, Mary Bussey, Wendel Naumann, James Hall, David Tait, Michael Haake. (2007) Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer. American Journal of Obstetrics and Gynecology 197:2, 205.e1-205.e7
CrossRef230
Gary L. Eddy, Brian N. Bundy, William T. Creasman, Nick M. Spirtos, Robert S. Mannel, Edward Hannigan, Dennis O’Connor. (2007) Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group. Gynecologic Oncology 106:2, 362-369
CrossRef231
Chel Hun Choi, Jeong-Won Lee, Tae-Joong Kim, Woo Young Kim, Hee Rim Nam, Byoung-Gie Kim, Seung Jae Huh, Je-Ho Lee, Duk-Soo Bae. (2007) Phase II Study of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer: Preliminary Results. International Journal of Radiation Oncology*Biology*Physics 68:3, 817-822
CrossRef232
I.L. ATAHAN, F. YILDIZ, E. OZYAR, B. PEHLIVAN, M. GENC, M.F. KOSE, G. TULUNAY, A. AYHAN, K. YUCE, N. GULER, T. KUCUKALI. (2007) Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. International Journal of Gynecological Cancer 17:4, 813-820
CrossRef233
William Small, Kathryn Winter, Charles Levenback, Revathy Iyer, David Gaffney, Sucha Asbell, Beth Erickson, Anuja Jhingran, Kathy Greven. (2007) Extended-Field Irradiation and Intracavitary Brachytherapy Combined With Cisplatin Chemotherapy for Cervical Cancer With Positive Para-Aortic or High Common Iliac Lymph Nodes: Results of ARM 1 of RTOG 0116. International Journal of Radiation Oncology*Biology*Physics 68:4, 1081-1087
CrossRef234
I.L. ATAHAN, C. ONAL, E. OZYAR, F. YILIZ, U. SELEK, F. KOSE. (2007) Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study. International Journal of Gynecological Cancer 17:4, 833-842
CrossRef235
Kung-Liahng Wang. (2007) Current Trends in Treating Cervical Cancer. International Journal of Gerontology 1:2, 98-102
CrossRef236
David K. Gaffney, Andreas Du Bois, Kailash Narayan, Nick Reed, Takafumi Toita, Sandro Pignata, Peter Blake, Lorraine Portelance, Azmat Sadoyze, Richard Pötter, Alessandro Colombo, Marcus Randall, Mansoor R. Mirza, Edward L. Trimble. (2007) Practice Patterns of Radiotherapy in Cervical Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG). International Journal of Radiation Oncology*Biology*Physics 68:2, 485-490
CrossRef237
Akiva P. Novetsky, Mark H. Einstein, Gary L. Goldberg, Susan M. Hailpern, Evan Landau, Abbie L. Fields, Subhakar Mutyala, Shalom Kalnicki, Madhur Garg. (2007) Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer. Gynecologic Oncology 105:3, 635-640
CrossRef238
Jennifer F. De Los Santos, Gillian M. Thomas. (2007) Anemia correction in malignancy management: Threat or opportunity?. Gynecologic Oncology 105:2, 517-529
CrossRef239
Sushil Beriwal, Gregory N. Gan, Dwight E. Heron, Raj N. Selvaraj, Hayeon Kim, Ron Lalonde, Joseph L. Kelley, Robert P. Edwards. (2007) Early Clinical Outcome With Concurrent Chemotherapy and Extended-Field, Intensity-Modulated Radiotherapy for Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 68:1, 166-171
CrossRef240
William F. Regine, Nader Hanna, Michael C. Garofalo, Austin Doyle, Susanne Arnold, Ritesh Kataria, Jacqueline Sims, Ming Tan, Mohammed Mohiuddin. (2007) Low-Dose Radiotherapy as a Chemopotentiator of Gemcitabine in Tumors of the Pancreas or Small Bowel: A Phase I Study Exploring a New Treatment Paradigm. International Journal of Radiation Oncology*Biology*Physics 68:1, 172-177
CrossRef241
Eric Leblanc, Fabrice Narducci, Michael Frumovitz, Anne Lesoin, Bernard Castelain, Marie C. Baranzelli, Sophie Taieb, Charles Fournier, Denis Querleu. (2007) Therapeutic value of pretherapeutic extraperitoneal laparoscopic staging of locally advanced cervical carcinoma. Gynecologic Oncology 105:2, 304-311
CrossRef242
G. Houvenaeghel, L. Lelievre, M. Buttarelli, J. Jacquemier, X. Carcopino, P. Viens, L. Gonzague-Casabianca. (2007) Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma. European Journal of Surgical Oncology (EJSO) 33:4, 498-503
CrossRef243
E.L. TRIMBLE, J. DAVIS, P. DISAIA, K. FUJIWARA, D. GAFFNEY, G. KRISTENSEN, J. LEDERMANN, J. PFISTERER, M. QUINN, N. REED, M. SCHOENFELDT, J.T. THIGPEN, . (2007) Clinical trials in gynecological cancer. International Journal of Gynecological Cancer 17:3, 547-556
CrossRef244
Miao-Fen Chen, Chih-Jen Tseng, Ching-Cheng Tseng, Yuen-Chun Kuo, Chun-Yen Yu, Wen-Cheng Chen. (2007) Clinical Outcome in Posthysterectomy Cervical Cancer Patients Treated With Concurrent Cisplatin and Intensity-Modulated Pelvic Radiotherapy: Comparison With Conventional Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 67:5, 1438-1444
CrossRef245
John Latimer. (2007) Gynaecological malignancies in pregnancy. Current Opinion in Obstetrics and Gynecology 19:2, 140-144
CrossRef246
Gabriella Ferrandina, Enrica Martinelli, Gian Franco Zannoni, Mariagrazia Distefano, Amelia Paglia, Cristiano Ferlini, Giovanni Scambia. (2007) Expression of class III β tubulin in cervical cancer patients administered preoperative radiochemotherapy: Correlation with response to treatment and clinical outcome. Gynecologic Oncology 104:2, 326-330
CrossRef247
Spyridon Tzioras, Nicholas Pavlidis, Evangelos Paraskevaidis, John P.A. Ioannidis. (2007) Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis. Cancer Treatment Reviews 33:1, 24-38
CrossRef248
Ludy Lutgens, Guido Lammering, Madelon Pijls-Johannesma, Jacoba van der Zee, Philippe Lambin, Dirk K M De Ruysscher, Jean-Marie Deneufbourg, Ludy Lutgens. 2007. Combined use of hyperthermia and radiation therapy for treating locally advanced cervical cancer. .
CrossRef249
Werner Dobrowsky, Nagraj G. Huigol, Ranapala S. Jayatilake, Noor-I-Alam Kizilbash, Sait Okkan, V. Tsutomu Kagiya, Hideo Tatsuzaki. (2007) AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial. Radiotherapy and Oncology 82:1, 24-29
CrossRef250
Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae. (2007) Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2–IIB cervical carcinoma. Gynecologic Oncology 104:1, 64-69
CrossRef251
H.-S. RYU, S.B. KANG, K.-T. KIM, K.-H. CHANG, J.W. KIM, J.-H. KIM, . (2007) Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). International Journal of Gynecological Cancer 17:1, 132-136
CrossRef252
Jeong Eun Lee, Youngyih Han, Seung Jae Huh, Won Park, Min Gyu Kang, Yong Chan Ahn, Do Hoon Lim. (2007) Interfractional variation of uterine position during radical RT: Weekly CT evaluation. Gynecologic Oncology 104:1, 145-151
CrossRef253
Mark H. Einstein, Akiva P. Novetsky, Madhur Garg, Susan M. Hailpern, Gloria S. Huang, Arielle Glueck, Abbie L. Fields, Shalom Kalnicki, Gary L. Goldberg. (2007) Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer 109:1, 48-53
CrossRef254
Me-Yeon Lee, Hong-Gyun Wu, Kyubo Kim, Sung Whan Ha, Jae Sung Kim, In Ah Kim, Hyo-Pyo Lee. (2007) Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecologic Oncology 104:1, 95-99
CrossRef255
Yong Bae Kim, Jae Ho Cho, Ki Chang Keum, Chang Geol Lee, Jinsil Seong, Chang Ok Suh, Gwi Eon Kim. (2007) Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecologic Oncology 104:1, 58-63
CrossRef256
Vutisiri Veerasarn, Vicharn Lorvidhaya, Pimkhuan Kamnerdsupaphon, Nan Suntornpong, Supatra Sangruchi, Prasert Lertsanguansinchai, Chonlakiet Khorprasert, Lak Sookpreedee, Suthipol Udompunturak. (2007) A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary results. Gynecologic Oncology 104:1, 15-23
CrossRef257
Anand Parthasarathy, Michael K. Cheung, Kathryn Osann, Amreen Husain, Nelson N. Teng, Jonathan S. Berek, Daniel S. Kapp, John K. Chan. (2006) The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecologic Oncology 103:3, 1095-1099
CrossRef258
Paul A. DiSilvestro, Joan L. Walker, Astrid Morrison, Peter G. Rose, Howard Homesley, David Warshal. (2006) Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the Gynecologic Oncology Group. Gynecologic Oncology 103:3, 1038-1042
CrossRef259
S KEHOE. (2006) Treatments for gynaecological cancers. Best Practice & Research Clinical Obstetrics & Gynaecology 20:6, 985-1000
CrossRef260
Eduard Vrdoljak, Tomislav Omrčen, Žana Saratlija Novaković, Tihana Boraska Jelavić, Tomislav Prskalo, Dario Hrepić, Wolfgang Hamm. (2006) Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix—Final results of a prospective phase II-study. Gynecologic Oncology 103:2, 494-499
CrossRef261
Gabriella Ferrandina, Mariagrazia Distefano, Daniela Smaniotto, Alessio Morganti, Amelia Paglia, Gabriella Macchia, Barbara Corvari, Domenica Lorusso, Giovanni Scambia. (2006) Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: Association with pathological response to treatment and clinical outcome. Gynecologic Oncology 103:2, 500-505
CrossRef262
Astrid Baalbergen, Anca Ansink, Lukas L Stalpers, Yerney Veenstra, Astrid Baalbergen. 2006. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. .
CrossRef263
Tatsuya Ohno, Shingo Kato, Masaru Wakatsuki, Shin-ei Noda, Chiemi Murakami, Misako Nakamura, Hirohiko Tsujii. (2006) Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: Comparison with radiation therapy alone. Gynecologic Oncology 103:1, 94-99
CrossRef264
Vandana Keskar, Prem S. Mohanty, Ernest J. Gemeinhart, Richard A. Gemeinhart. (2006) Cervical cancer treatment with a locally insertable controlled release delivery system. Journal of Controlled Release 115:3, 280-288
CrossRef265
R MARTINEZMONGE, M JURADO, M CAMBEIRO, J VALERO, E VILLAFRANCA, J ALCAZAR. (2006) Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecologic cancer: Initial results of a phase II trial. Brachytherapy 5:4, 203-210
CrossRef266
Takafumi Toita. (2006) Concurrent chemoradiation for cervical cancer: what should we do next?. International Journal of Clinical Oncology 11:4, 253-255
CrossRef267
Yoh Watanabe, Hidekatsu Nakai, Masao Shimaoka, Takako Tobiume, Isao Tsuji, Hiroshi Hoshiai. (2006) Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. International Journal of Clinical Oncology 11:4, 309-313
CrossRef268
Setsuko Kawase, Takahito Okuda, Mitsuru Ikeda, Shunichi Ishihara, Yoshiyuki Itoh, Shigeo Yanagawa, Takeo Ishigaki. (2006) Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer. Gynecologic Oncology 102:3, 493-499
CrossRef269
J.M. Classe, P. Rauch, J.F. Rodier, P. Morice, E. Stoeckle, S. Lasry, G. Houvenaeghel. (2006) Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: Morbidity and outcome: Results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecologic Oncology 102:3, 523-529
CrossRef270
Y.S. CHOI, C.M. YI, J.-I. SIN, G.W. YE, I.H. SHIN, T.S. LEE. (2006) Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. International Journal of Gynecological Cancer 16:5, 1846-1854
CrossRef271
G. Hänsgen. (2006) Radiochemotherapie beim Zervixkarzinom. Der Onkologe 12:9, 917-922
CrossRef272
Frank J.P. Hoebers, Dick Pluim, Marcel Verheij, Alfons J.M. Balm, Harry Bartelink, Jan H.M. Schellens, Adrian C. Begg. (2006) Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). International Journal of Cancer 119:4, 750-756
CrossRef273
Kristina Gerszten, Kelly Colonello, Dwight E. Heron, Ron J. Lalonde, Issa D. Fitian, John T. Comerci, Raj N. Selvaraj, John M. Varlotto. (2006) Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecologic Oncology 102:2, 182-188
CrossRef274
C. NYONGESA, P. RUFF, B. DONDE, J. KOTZEN. (2006) A phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy. International Journal of Gynecological Cancer 16:4, 1614-1619
CrossRef275
Gilles Houvenaeghel, Loic Lelievre, Anne-Laure Rigouard, Max Buttarelli, Jocelyne Jacquemier, Patrice Viens, Laurence Gonzague-Casabianca. (2006) Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Gynecologic Oncology 102:1, 74-79
CrossRef276
Elizabeth M. Swisher, Ron E. Swensen, Benjamin Greer, Hisham Tamimi, Barbara A. Goff, Rochelle Garcia, Wui-jin Koh. (2006) Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: A phase I trial of the Puget Sound Oncology Consortium. Gynecologic Oncology 101:3, 429-435
CrossRef277
John M. Varlotto, Kristina Gerszten, Dwight E. Heron, John Comerci, Shiva Gautam, Raj Selvaraj, Ron Lalonde, Justin C. Chura. (2006) The Potential Nephrotoxic Effects of Intensity Modulated Radiotherapy Delivered to the Para-Aortic Area of Women With Gynecologic Malignancies. American Journal of Clinical Oncology 29:3, 281-289
CrossRef278
Kyubo Kim, Eui Kyu Chie, Hong-Gyun Wu, Sung W. Ha, Jae Sung Kim, In Ah Kim, Hyo-Pyo Lee. (2006) Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecologic Oncology 101:3, 398-402
CrossRef279
Kiichiro Noda, Yasuo Ohashi, Hajime Sugimori, Masami Ozaki, Hideo Niibe, Sachio Ogita, Ichiro Kohno, Kazuo Hasegawa, Yuzo Kikuchi, Yoshihiro Takegawa, Shingo Fujii, Kenichi Tanaka, Kazunori Ochiai, Midori Kita, Keiichi Fujiwara. (2006) Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: Treatment with immunomodulator, more is not better. Gynecologic Oncology 101:3, 455-463
CrossRef280
T-J Kim, J-W Lee, S Y Song, J-J Choi, C H Choi, B-G Kim, J-H Lee, D-S Bae. (2006) Increased expression of pAKT is associated with radiation resistance in cervical cancer. British Journal of Cancer
CrossRef281
David H. Moore. (2006) Cervical Cancer. Obstetrics & Gynecology 107:5, 1152-1161
CrossRef282
Q.D. PIETERSE, C.P. MAAS, M.M. TER KUILE, M. LOWIK, M.A. VAN EIJKEREN, J.B.M.Z. TRIMBOS, G.G. KENTER. (2006) An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. International Journal of Gynecological Cancer 16:3, 1119-1129
CrossRef283
N.R. Datta, S. Agrawal. (2006) Does the Evidence Support the Use of Concurrent Chemoradiotherapy as a Standard in the Management of Locally Advanced Cancer of the Cervix, Especially in Developing countries?. Clinical Oncology 18:4, 306-312
CrossRef284
L. GOEDHALS, A.L. van WIYK, B.L. SMITH, S.J. FOURIE. (2006) Pemetrexed (AlimtaR, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. International Journal of Gynecological Cancer 16:3, 1172-1178
CrossRef285
John P. Micha, Bram H. Goldstein, Mark A. Rettenmaier, James T. Caillouette, Martin J. Fee, John V. Brown. (2006) Pelvic radiation necrosis and osteomyelitis following chemoradiation for advanced stage vulvar and cervical carcinoma. Gynecologic Oncology 101:2, 349-352
CrossRef286
J. Sehouli, W. Lichtenegger. (2006) Aktuelles Management des Zervixkarzinoms. Der Gynäkologe 39:5, 379-394
CrossRef287
Patricia J Eifel. (2006) Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nature Clinical Practice Oncology 3:5, 248-255
CrossRef288
J. Michael Straughn, Patsy G. Oliver, Tong Zhou, Wenquan Wang, Ronald D. Alvarez, William E. Grizzle, Donald J. Buchsbaum. (2006) Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecologic Oncology 101:1, 46-54
CrossRef289
Kristin A. Bradley, Daniel G. Petereit. (2006) Radiation Therapy for Gynecologic Malignancies. Hematology/Oncology Clinics of North America 20:2, 347-361
CrossRef290
L. SELVAGGI, V. LOIZZI, A. R. DI GILIO, C. NARDELLI, C. CANTATORE, G. CORMIO. (2006) Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience. International Journal of Gynecological Cancer 16:2, 631-637
CrossRef291
M. King, C. McConkey, T.N. Latief, A. Hartley, I. Fernando. (2006) Improved Survival After Concurrent Weekly Cisplatin and Radiotherapy for Cervical Carcinoma with Assessment of Acute and Late Side-effects. Clinical Oncology 18:1, 38-45
CrossRef292
C.T. Thomas, A. Ammar, J.J. Farrell, H. Elsaleh. (2006) Radiation Modifiers: Treatment Overview and Future Investigations. Hematology/Oncology Clinics of North America 20:1, 119-139
CrossRef293
Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, D. Scott McMeekin, Shashikant Lele, Susan L. Zweizig. (2006) Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecologic Oncology 100:2, 385-388
CrossRef294
Gilles Houvenaeghel, Loic Lelievre, Laurence Gonzague-Casabianca, Max Buttarelli, Vincent Moutardier, Anthony Goncalves, Michel Resbeut. (2006) Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecologic Oncology 100:2, 338-343
CrossRef295
Rakesh R. Patel, Douglas W. Arthur. (2006) The Emergence of Advanced Brachytherapy Techniques for Common Malignancies. Hematology/Oncology Clinics of North America 20:1, 97-118
CrossRef296
M.C. Fernández-Fernández, J.C. Fernández-Fernández, M.J. Jiménez-Torres, J.A. Vargas. (2006) Radioquimioterapia en el carcinoma localmente avanzado de cérvix. Clínica e Investigación en Ginecología y Obstetricia 33:1, 2-6
CrossRef297
Hitoshi Ikushima, Kyousuke Osaki, Shunsuke Furutani, Kyou Yamashita, Takashi Kawanaka, Yoshiomi Kishida, Seiji Iwamoto, Yoshihiro Takegawa, Takaharu Kudoh, Hiromu Nishitani. (2006) Chemoradiation therapy for cervical cancer: Toxicity of concurrent weekly cisplatin. Radiation Medicine 24:2, 115-121
CrossRef298
Riadh Chargui, Tarak Damak, Fethi Khomsi, Jamel Ben Hassouna, Walid Chaieb, Monia Hechiche, Amor Gamoudi, Hamouda Boussen, Farouk Benna, Khaled Rahal. (2006) Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. American Journal of Obstetrics and Gynecology 194:1, 43-48
CrossRef299
Youn Seok Choi, Jeong-Im Sin, Ju Hyun Kim, Gi Won Ye, Im Hee Shin, Tae Sung Lee. (2006) Survival Benefits of Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy in Locally Advanced Chemoresistant Cervical Cancer. Journal of Korean Medical Science 21:4, 683
CrossRef300
J. Umanzor, M. Aguiluz, C. Pineda, S. Andrade, M. Erazo, Claudio Flores, Sergio Santillana. (2006) Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: A phase II trial. Gynecologic Oncology 100:1, 70-75
CrossRef301
L. Miglietta, P. Franzone, M.G. Centurioni, L. Boni, L. Tacchini, M. Cosso, F. Boccardo, M. Ferrarini, M. Bruzzone. (2006) A Phase II Trial with Cisplatin-Paclitaxel Cytotoxic Treatment and Concurrent External and Endocavitary Radiation Therapy in Locally Advanced or Recurrent Cervical Cancer. Oncology 70:1, 19-24
CrossRef302
Distefano Mariagrazia, Fagotti Anna, Ferrandina Gabriella, Fanfani Francesco, Smaniotto Daniela, D'Agostino Giuseppe, Morganti Alessio, Scambia Giovanni. (2005) Preoperative chemoradiotherapy in locally advanced cervical cancer: Long-term outcome and complications. Gynecologic Oncology 99:3, S166-S170
CrossRef303
Krishnansu S. Tewari, Bradley J. Monk. (2005) Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Current Oncology Reports 7:6, 419-434
CrossRef304
Isabelle Cadron, Frederic Amant, Ignace Vergote. (2005) Chemotherapy for cervical cancer. European Clinics in Obstetrics and Gynaecology 1:3, 143-150
CrossRef305
Murat Sonmezer, Mousa Issa Shamonki, Kutluk Oktay. (2005) Ovarian tissue cryopreservation: benefits and risks. Cell and Tissue Research 322:1, 125-132
CrossRef306
Catheryn M. Yashar, William J. Spanos, Douglas D. Taylor, Cicek Gercel-Taylor. (2005) Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecologic Oncology 99:1, 199-205
CrossRef307
Francisco José Andreu-Martínez, Julia M. Martínez-Mateu. (2005) Hypoxia and anaemia in patients with cancer of the uterine cervix. Clinical and Translational Oncology 7:8, 323-331
CrossRef308
E.P. SAIBISHKUMAR, F.D. PATEL, S.C. SHARMA. (2005) Results of radiotherapy alone in the treatment of carcinoma of uterine cervix: a retrospective analysis of 1069 patients. International Journal of Gynecological Cancer 15:5, 890-897
CrossRef309
Luis A Rojas-Espaillat, Peter G Rose. (2005) Management of locally advanced cervical cancer. Current Opinion in Oncology 17:5, 485-492
CrossRef310
Anneke M. Westermann, Ellen L. Jones, Baard-Christian Schem, Elzbieta M. van der Steen-Banasik, Peter Koper, Olav Mella, Apollonia L. J. Uitterhoeve, Ronald de Wit, Jacobus van der Velden, Curt Burger, Clasina L. van der Wilt, Olav Dahl, Leonard R. Prosnitz, Jacoba van der Zee. (2005) First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma. Cancer 104:4, 763-770
CrossRef311
John A Green, John J Kirwan, Jayne Tierney, Claire L Vale, Paul R Symonds, Lydia L Fresco, Chris Williams, Mandy Collingwood, John Green. 2005. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. .
CrossRef312
Krystyna Serkies, Jacek Jassem. (2005) Chemotherapy in the primary treatment of cervical carcinoma. Critical Reviews in Oncology/Hematology 54:3, 197-208
CrossRef313
Shalini Singh, Niloy R. Datta, Narendra Krishnani, Punita Lal, Shaleen Kumar. (2005) Radiation therapy induced micronuclei in cervical cancer—does it have a predictive value for local disease control?. Gynecologic Oncology 97:3, 764-771
CrossRef314
J.A. de Hullu, E. Pras, H. Hollema, A.G.J. van der Zee, D.H. Bogchelman, M.J.E. Mourits. (2005) Presentations of endometrial activity after curative radiotherapy for cervical cancer. Maturitas 51:2, 172-176
CrossRef315
Zuzana Stokes, Paul Symonds, Tim Habeshaw, Nick Reed, Jorge Curto, Claire Joynson, Steve Chan. (2005) Phase one dose finding study of capecitabine (Xeloda®), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer. Gynecologic Oncology 97:3, 790-795
CrossRef316
R. Rouzier, P. Morice, R. De Crevoisier, C. Pomel, A. Rey, K. Bonnet, A. Recoules-Arche, P. Duvillard, C. Lhomme, C. Haie-Meder, D. Castaigne. (2005) Survival in cervix cancer patients treated with radiotherapy followed by radical surgery. European Journal of Surgical Oncology (EJSO) 31:4, 424-433
CrossRef317
Rodney P. Rocconi, Jacob M. Estes, Charles A. Leath, Larry C. Kilgore, Warner K. Huh, J. Michael Straughn. (2005) Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis. Gynecologic Oncology 97:2, 387-394
CrossRef318
W. Termrungruanglert, D. Tresukosol, A. Vasuratna, T. Sittisomwong, R. Lertkhachonsuk, N. Sirisabya. (2005) Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2. Gynecologic Oncology 97:2, 576-581
CrossRef319
Lucas B. Silva, Agnaldo L. Silva-Filho, Paulo Traiman, Sérgio A. Triginelli, Carla Flávia de Lima, Cristiano Ferrari Siqueira, Adelanir Barroso, Telma Maria F.F. Rossi, Moises Salgado Pedrosa, Dairton Miranda, José Renan Cunha Melo. (2005) Sentinel node detection in cervical cancer with 99mTc-phytate. Gynecologic Oncology 97:2, 588-595
CrossRef320
Elie Azria, Philippe Morice, Christine Haie-Meder, Anne Thoury, Patricia Pautier, Catherine Lhomme, Pierre Duvillard, Damienne Castaigne. (2005) Results of Hysterectomy in Patients With Bulky Residual Disease at the End of Chemoradiotherapy for Stage IB2/II Cervical Carcinoma. Annals of Surgical Oncology 12:4, 332-337
CrossRef321
Yih-Lin Chung, James Jer-Min Jian, Skye Hongiun Cheng, Cheng-I Hsieh, Tran-Der Tan, Hui-Ju Chang, Chi-Feng Hung, Cheng-Fang Horng, Thomas Soong, Mei-Hua Tsou. (2005) Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. Gynecologic Oncology 97:1, 126-135
CrossRef322
A DUENASGONZALEZ, L CETINAPEREZ, L ONATEOCANA, L RIVERA, C LOPEZGRANIEL, A GONZALEZENCISO, M CANDELARIA, A MOHAR. (2005) Multimodal Treatment of Locally Advanced Cervical Cancer. Archives of Medical Research 36:2, 129-135
CrossRef323
Shoji Nagao, Keiichi Fujiwara, Takashi Oda, Hiroyasu Ishikawa, Hirofumi Koike, Hiromasa Tanaka, Ichiro Kohno. (2005) Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecologic Oncology 96:3, 805-809
CrossRef324
Tawee Tanvetyanon, Joseph I. Clark, Steve C. Campbell, Simon S. Lo. (2005) Neoadjuvant Therapy: An Emerging Concept in Oncology. Southern Medical Journal 98:3, 338-344
CrossRef325
Wendy R. Brewster. (2005) Untreated Cervical Cancer. Gynecologic Oncology 96:2, 269-270
CrossRef326
Takashi Uno, Hisao Ito, Koichi Isobe, Yuko Kaneyasu, Naotake Tanaka, Akira Mitsuhashi, Kiyomi Suzuka, Koji Yamazawa, Naoyuki Shigematsu, Jun Itami. (2005) Postoperative pelvic radiotherapy for cervical cancer patients with positive parametrial invasion. Gynecologic Oncology 96:2, 335-340
CrossRef327
Geraldine M. Jacobson, Reena S. Kamath, Brian J. Smith, Michael J. Goodheart. (2005) Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecologic Oncology 96:2, 470-474
CrossRef328
Jin Ho Kim, Hak Jae Kim, Semie Hong, Hong-Gyun Wu, Sung Whan Ha. (2005) Post-hysterectomy radiotherapy in FIGO stage IB–IIB uterine cervical carcinoma. Gynecologic Oncology 96:2, 407-414
CrossRef329
Annie Yessaian, Alberto A. Mendivil, Wendy R. Brewster. (2005) Population characteristics in cervical cancer trials: Search for external validity. American Journal of Obstetrics and Gynecology 192:2, 407-413
CrossRef330
Hee-Sug Ryu, Mison Chun, Ki-Hong Chang, Hye-Jin Chang, Jung-Pil Lee. (2005) Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecologic Oncology 96:2, 490-495
CrossRef331
Maurie Markman. (2005) Reflections on Ethical Concerns Arising from the Incorporation of Results of Randomized Trials of Antineoplastic Therapy into Routine Clinical Practice. Cancer Investigation 23:8, 735-740
CrossRef332
Daniel T Rein, Peter Dall, Christian M Kurbacher, Martina Breidenbach. (2005) Developments and Current Treatment Standards in Cervical Cancer. American Journal of Cancer 4:6, 373-381
CrossRef333
Young Seok Kim, Seong Soo Shin, Eun Kyung Choi, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Heon-Jin Park, Young-Tak Kim, Jung-Eun Mok, Joo-Hyun Nam. (2005) A Preliminary Results of a Randomized Trial Comparing Monthly 5-flourouracil and Cisplatin to W eekly Cisplatin A lone Combined with Concurrent Radiotherapy for Locally Advanced Cervical Cancer. Cancer Research and Treatment 37:1, 37
CrossRef334
Akira Mitsuhashi, Takashi Uno, Naotake Tanaka, Kiyomi Suzuka, Shinichi Tate, Koji Yamazawa, Hideo Matsui, Seiji Yamamoto, Hisao Ito, Souei Sekiya. (2005) Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma. Gynecologic Oncology 96:1, 194-197
CrossRef335
Gabriele K. Beckmann, Florian Hoppe, Leo Pfreundner, Michael P. Flentje. (2005) Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head & Neck 27:1, 36-43
CrossRef336
Aljosa Mandic. (2005) Neoadjuvant chemotherapy in treatment of cervical cancer: Controversies. Archive of oncology 13:2, 89-90
CrossRef337
Juan E. Sardi, María A. Boixadera, Juan J. Sardi. (2004) A critical overview of concurrent chemoradiotherapy in cervical cancer. Current Oncology Reports 6:6, 463-470
CrossRef338
Jennifer F. De Los Santos, William Small. (2004) The role of amifostine in the treatment of carcinoma of the uterine cervix: An update of RTOG-0116 and review of future directions. Seminars in Oncology 31, 37-41
CrossRef339
N.R. Datta, R. Pasricha, U. Singh, A. Srivastava. (2004) Predictors of survival end points in patients with cancer of the cervix on long-term follow-up: inferences and implications from an audit of patients treated with a specific radiotherapy protocol. Clinical Oncology 16:8, 536-542
CrossRef340
Satoru Motoyama, Shinya Hamana, Yonson Ku, Jovelle B. Laoag-Fernandez, Masashi Deguchi, Shigeki Yoshida, Masahiro Tominaga, Takeshi Iwasaki, Noriyuki Ohara, Takeshi Maruo. (2004) Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa–IVa cervical cancer. Gynecologic Oncology 95:3, 576-582
CrossRef341
Franco M. Muggia. (2004) Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Seminars in Oncology 31, 17-24
CrossRef342
Rosa Tambaro, Giovanni Scambia, Massimo Di Maio, Carmela Pisano, Emiddio Barletta, Vincenzo Rosario Iaffaioli, Sandro Pignata. (2004) The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Critical Reviews in Oncology/Hematology 52:1, 33-44
CrossRef343
J.B. Trimbos, A.F. Lambeek, A.A.W. Peters, R. Wolterbeek, K.N. Gaarenstroom, G.J. Fleuren, G.G. Kenter. (2004) Prognostic difference of surgical treatment of exophytic versus barrel-shaped bulky cervical cancer. Gynecologic Oncology 95:1, 77-81
CrossRef344
S. K
mmel, A. Thomas, M. Hausschild, W. Lichtenegger, J.-U. Blohmer. (2004) Adjuvante Therapie beim Zervixkarzinom. Der Gyn
CrossRef345
Teresa L. Rutledge, Scott A. Kamelle, Todd D. Tillmanns, Natalie S. Gould, Jason D. Wright, David E. Cohn, Thomas J. Herzog, Janet S. Rader, Michael A. Gold, Gary A. Johnson, Joan L. Walker, Robert S. Mannel, D. Scott McMeekin. (2004) A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?. Gynecologic Oncology 95:1, 70-76
CrossRef346
Maurie Markman. (2004) Translating the results of phase III randomized cancer trials into the language of physician obligation to patients. Current Oncology Reports 6:4, 243-244
CrossRef347
R.P Symonds, M Collingwood, J Kirwan, C.E Humber, J.F Tierney, J.A Green, C Williams. (2004) Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. Cancer Treatment Reviews 30:5, 405-414
CrossRef348
Scott A Kamelle, Teresa L Rutledge, Todd D Tillmanns, Natalie S Gould, David E Cohn, Jason Wright, Thomas J Herzog, Janet S Rader, Michael A Gold, Gary A Johnson, Joan L Walker, Robert S Mannel, D Scott McMeekin. (2004) Surgical–pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?. Gynecologic Oncology 94:2, 249-255
CrossRef349
William E Winter, G.Larry Maxwel, Chunqiao Tian, Eugene Sobel, G Scott Rose, Gillian Thomas, Jay W Carlson. (2004) Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecologic Oncology 94:2, 495-501
CrossRef350
Melissa A. Decker, James J. Burke, Donald G. Gallup, Robert W. Silverio, David Weems, John Duttenhaver, Dent Purcell. (2004) Completion hysterectomy after radiation therapy for bulky cervical cancer stages IB, IIA, and IIB: Complications and survival rates. American Journal of Obstetrics and Gynecology 191:2, 654-658
CrossRef351
(2004) Discussion. American Journal of Obstetrics and Gynecology 191:2, 658-660
CrossRef352
Rachel A Dubay, Peter G Rose, David M O'Malley, Abdelwahab D Shalodi, Adir Ludin, Mostafa A Selim. (2004) Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecologic Oncology 94:1, 121-124
CrossRef353
Juan Luis Alc
CrossRef354
Ayman Saad, Simon S. Lo, Ihn Han, Sameer Keole, Charles P. Lee, Sam Tekyi-Mensah, Adnan Munkarah, John Malone, Robert Morris, Gunter Deppe. (2004) Radiation Therapy With or Without Chemotherapy for Cervical Cancer With Periaortic Lymph Node Metastasis. American Journal of Clinical Oncology 27:3, 256-263
CrossRef355
L.T. Tan, S. Russell, L. Burgess. (2004) Acute Toxicity of Chemo-radiotherapy for Cervical Cancer: The Addenbrooke’s Experience. Clinical Oncology 16:4, 255-260
CrossRef356
Margrit M Juretzka, Kristin C Jensen, Teri A Longacre, Nelson N Teng, Amreen Husain. (2004) Detection of pelvic lymph node micrometastasis in stage IA2–IB2 cervical cancer by immunohistochemical analysis. Gynecologic Oncology 93:1, 107-111
CrossRef357
Emmanuel Barranger, Annie Cortez, Dany Grahek, Patrice Callard, Serge Uzan, Emile Darai. (2004) Laparoscopic Sentinel Node Procedure for Cervical Cancer: Impact of Neoadjuvant Chemoradiotherapy. Annals of Surgical Oncology 11:4, 445-452
CrossRef358
Andrea Fattorossi, Alessandra Battaglia, Gabriella Ferrandina, Ferdinando Coronetta, Francesco Legge, Vanda Salutari, Giovanni Scambia. (2004) Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 100:7, 1418-1428
CrossRef359
Takeshi Kodaira, Nobukazu Fuwa, Toru Nakanishi, Kazuo Kuzuya, Masahiro Sasaoka, Hiroyuki Tachibana, Kazuhisa Furutani. (2004) Long-Term Clinical Outcomes of Postoperative Pelvic Radiotherapy With or Without Prophylactic Paraaortic Irradiation for Stage I-II Cervical Carcinoma With Positive Lymph Nodes. American Journal of Clinical Oncology 27:2, 140-148
CrossRef360
Hemant B Tongaonkar. (2004) Changing practice of gynecologic oncology based on current evidence. Medical Journal Armed Forces India 60:2, 102-106
CrossRef361
Andreas Widschwendter, Lennart Ivarsson, Anya Blassnig, Hannes M. M
CrossRef362
José M Martı́nez-Palones, Antonio Gil-Moreno, Marı́a A Pérez-Benavente, Isabel Roca, Jordi Xercavins. (2004) Intraoperative sentinel node identification in early stage cervical cancer using a combination of radiolabeled albumin injection and isosulfan blue dye injection. Gynecologic Oncology 92:3, 845-850
CrossRef363
Joseph K. Salama, John C. Roeske, Neil Mehta, Arno J. Mundt. (2004) Intensity-modulated radiation therapy in gynecologic malignancies. Current Treatment Options in Oncology 5:2, 97-108
CrossRef364
Saban Cakir, Ibrahim Egehan. (2004) A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43:3, 309-316
CrossRef365
H. Lin, C.-L. Chang, E.-Y. Huang, C.-C. Changchien. (2004) Early-onset sigmoid colon perforation during concurrent chemoradiation in a patient with cervical cancer. International Journal of Gynecological Cancer 14:2, 381-383
CrossRef366
Arno J Mundt, Jacob Rotmensch, Steven E Waggoner, S.Diane Yamada, Gini F Fleming. (2004) Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecologic Oncology 92:3, 801-805
CrossRef367
John O. Schorge, Lynne M. Knowles, Jayanthi S. Lea. (2004) Adenocarcinoma of the cervix. Current Treatment Options in Oncology 5:2, 119-127
CrossRef368
Jonathan Markman, Kristine Zanotti, Kenneth Webster, Jerome Belinson, Gertrude Peterson, Barbara Kulp, Maurie Markman. (2004) Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecologic Oncology 92:2, 592-595
CrossRef369
Michiko Aoki, Jun-ichi Akahira, Hitoshi Niikura, Sumika Saito, Yoriko Abe, Takeshi Aida, Naoko Sato, Takako Kitamura, Kenro Otsuki, Atsuko Katahira, Hiroki Utsunomiya, Chikako Okamura, Tadao Takano, Kiyoshi Ito, Kunihiro Okamura, Nobuo Yaegashi. (2004) Retrospective Analysis of Concurrent Chemoradiation with the Combination of Bleomycin, Ifosfamide and Cisplatin (BIP) for Uterine Cervical Cancer. The Tohoku Journal of Experimental Medicine 204:4, 309-315
CrossRef370
Mariagrazia Distefano, Gabriella Ferrandina, Daniela Smaniotto, Alessandro Pasquale Margariti, Gianfranco Zannoni, Gabriella Macchia, Riccardo Manfredi, Maria Grazia Mangiacotti, Numa Cellini, Giovanni Scambia. (2004) Concomitant Radiochemotherapy plus Surgery in Locally Advanced Cervical Cancer: Update of Clinical Outcome and Cyclooxygenase-2 as Predictor of Treatment Susceptibility. Oncology 67:2, 103-111
CrossRef371
John A Green, Alberto de Barros Lopes. (2004) Optimizing Treatment for Cervical Cancer. American Journal of Cancer 3:4, 215-227
CrossRef372
Pernille T. Jensen, Mogens Groenvold, Marianne C. Klee, Ingrid Thranov, Morten Aa. Petersen, David Machin. (2004) Early-stage cervical carcinoma, radical hysterectomy, and sexual function. Cancer 100:1, 97-106
CrossRef373
Takeshi Kodaira, Nobukazu Fuwa, Takafumi Toita, Yoshihito Nomoto, Kazuo Kuzuya, Kazuyuki Tachibana, Kazuhisa Furutani, Kazuhiko Ogawa. (2003) Clinical Evaluation Using Magnetic Resonance Imaging for Patients With Stage III Cervical Carcinoma Treated by Radiation Alone in Multicenter Analysis. American Journal of Clinical Oncology 26:6, 574-583
CrossRef374
J.H Maduro, E Pras, P.H.B Willemse, E.G.E de Vries. (2003) Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treatment Reviews 29:6, 471-488
CrossRef375
William Small. (2003) Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the radiation therapy oncology group C-0116 trial. Seminars in Oncology 30, 68-71
CrossRef376
Y. Niibe, T. Nakano, T. Ohno, Y. Suzuki, K. Oka, H. Tsujii. (2003) Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. International Journal of Gynecological Cancer 13:6, 849-855
CrossRef377
Harry J. Long. (2003) Current research directions for locally advanced cervix cancer. Current Oncology Reports 5:6, 468-472
CrossRef378
Frederick B. Stehman, Peter G. Rose, Benjamin E. Greer, Michel Roy, Marie Plante, Manuel Penalver, Anuja Jhingran, Patricia Eifel, Fredrick Montz, J. Taylor Wharton. (2003) Innovations in the treatment of invasive cervical cancer. Cancer 98:S9, 2052-2063
CrossRef379
Maurie Markman. (2003) Toxicities of the platinum antineoplastic agents. Expert Opinion on Drug Safety 2:6, 597-607
CrossRef380
Carlos T. Vallejo, Mario R. Machiavelli, Juan E. P??rez, Alberto O. Romero, Fabrina Bologna, Hern??n Vicente, Juan A. Lacava, Eduardo H. Ortiz, Alberto Cubero, Guillermo Focaccia, Guillermo Suttora, Mirna Scenna, Jos?? M. Boughen, Bernardo A. Leone. (2003) Docetaxel as Neoadjuvant Chemotherapy in Patients With Advanced Cervical Carcinoma. American Journal of Clinical Oncology 26:5, 477-482
CrossRef381
Ted Wun, Lisa Law, Danielle Harvey, Barbara Sieracki, Sidney A. Scudder, Janice K. Ryu. (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98:7, 1514-1520
CrossRef382
David H Moore. (2003) Treatment of stage IB2 (bulky) cervical carcinoma. Cancer Treatment Reviews 29:5, 401-406
CrossRef383
Alfonso Dueñas-Gonzalez, Lucely Cetina, Ignacio Mariscal, Jaime de la Garza. (2003) Modern management of locally advanced cervical carcinoma. Cancer Treatment Reviews 29:5, 389-399
CrossRef384
V. Loizzi, G. Cormio, G. Loverro, L. Selvaggi, P. J. Disaia, F. Cappuccini. (2003) Chemoradiation: A new approach for the treatment of cervical cancer. International Journal of Gynecological Cancer 13:5, 580-586
CrossRef385
A. Obermair, R. Cheuk, K. Horwood, M. Neudorfer, M. Janda, G. Giannis, J.L. Nicklin, L.C. Perrin, A.J. Crandon. (2003) Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. International Journal of Gynecological Cancer 13:5, 633-639
CrossRef386
Tate Thigpen. (2003) The Role of Chemotherapy in the Management of Carcinoma of the Cervix. The Cancer Journal 9:5, 425-432
CrossRef387
James V. Fiorica. (2003) The role of topotecan in the treatment of advanced cervical cancer. Gynecologic Oncology 90:3, S16-S21
CrossRef388
Jeanne M. Schilder, Frederick B. Stehman. (2003) Stage Ia-IIa Cancer of the Cervix. The Cancer Journal 9:5, 395-403
CrossRef389
Peter G. Rose. (2003) Stage IIB-IVA Cancer of the Cervix. The Cancer Journal 9:5, 404-414
CrossRef390
Thomas J Herzog. (2003) New approaches for the management of cervical cancer. Gynecologic Oncology 90:3, S22-S27
CrossRef391
Craig A MacLeod, Shalini K Vinod. (2003) Early cervical cancer treated with definitive or adjuvant radiotherapy: Improved survival with adjuvant radiotherapy attributable to patient selection. Australasian Radiology 47:3, 279-283
CrossRef392
David G Mutch, Jeffrey D Bloss. (2003) Gemcitabine in cervical cancer. Gynecologic Oncology 90:2, S8-S15
CrossRef393
S. Sundar, P. Symonds, C. Deehan. (2003) Tolerance of Pelvic Organs to Radiation Treatment for Carcinoma of Cervix. Clinical Oncology 15:5, 240-247
CrossRef394
Ellen L. Jones, Thaddeus V. Samulski, Mark W. Dewhirst, Angeles Alvarez-Secord, Andrew Berchuck, Daniel Clarke-Pearson, Laura J. Havrilesky, John Soper, Leonard R. Prosnitz. (2003) A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 98:2, 277-282
CrossRef395
Evelyne L Weaver, Rathindra N Bose. (2003) Platinum(II) catalysis and radical intervention in reductions of platinum(IV) antitumor drugs by ascorbic acid. Journal of Inorganic Biochemistry 95:4, 231-239
CrossRef396
Geza Acs, Paul J. Zhang, Cindy M. McGrath, Peter Acs, John McBroom, Ahmed Mohyeldin, Suzhen Liu, Huasheng Lu, Ajay Verma. (2003) Hypoxia-Inducible Erythropoietin Signaling in Squamous Dysplasia and Squamous Cell Carcinoma of the Uterine Cervix and Its Potential Role in Cervical Carcinogenesis and Tumor Progression. The American Journal of Pathology 162:6, 1789-1806
CrossRef397
Henry M Keys, Brian N Bundy, Frederick B Stehman, Takashi Okagaki, Donald G Gallup, Alexander F Burnett, Marvin Z Rotman, Wesley C Fowler. (2003) Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group
. Gynecologic Oncology 89:3, 343-353
CrossRef398
David H Moore. (2003) Neoadjuvant chemotherapy for cervical cancer. Expert Opinion on Pharmacotherapy 4:6, 859-867
CrossRef399
Robert V Higgins, Wendel R Naumann, James B Hall, Michael Haake. (2003) Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecologic Oncology 89:3, 499-503
CrossRef400
Anthony H. Russell. (2003) All, none, or some?. Gynecologic Oncology 89:3, 341-342
CrossRef401
Steven E Waggoner. (2003) Cervical cancer. The Lancet 361:9376, 2217-2225
CrossRef402
Jennifer H Menell, Dennis S Chi, Lucy E Hann, Hedvig Hricak. (2003) The use of MRI in the diagnosis and management of a bulky cervical carcinoma. Gynecologic Oncology 89:3, 517-521
CrossRef403
A. D. Colevas, J. M. Brown, S. Hahn, J. Mitchell, K. Camphausen, C. N. Coleman. (2003) Development of Investigational Radiation Modifiers. JNCI Journal of the National Cancer Institute 95:9, 646-651
CrossRef404
Julie J Huh, Judith K Wolf, Diane L Fightmaster, Reuben Lotan, Michele Follen. (2003) Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecologic Oncology 89:2, 243-250
CrossRef405
Brij M. Sood, Giridhar R. Gorla, Madhur Garg, Patrick S. Anderson, Abbie L. Fields, Carolyn D. Runowicz, Gary L. Goldberg, Bhadrasain Vikram. (2003) Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix. Cancer 97:7, 1781-1788
CrossRef406
Russell Hogg, Michael Friedlander. (2003) Role of systemic chemotherapy in metastatic cervical cancer. Expert Review of Anticancer Therapy 3:2, 234-240
CrossRef407
Arthur Hung, Christopher Crane, Marc Delclos, Matthew Ballo, Jaffer Ajani, Edward Lin, Barry Feig, John Skibber, Nora Janjan. (2003) Cisplatin-based combined modality therapy for anal carcinoma. Cancer 97:5, 1195-1202
CrossRef408
H. -J. Huang, T. -C. Chang, J. -H. Hong, C. -J. Tseng, H. -H. Chou, K. -G. Huang, C. -H. Lai. (2003) Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (>=4 cm) stage IB and IIA cervical carcinoma. International Journal of Gynecological Cancer 13:2, 204-211
CrossRef409
R. Yazigi, G. Aliste, R. Torres, A. M. Ciudad, M. Cuevas, J. Garrido, S. Prado, A. Sola, R. Castillo, B. Cerda, M. A. Cumsille, M. Gonzalez, C. Navarro, J. M. Reyes. (2003) Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix. International Journal of Gynecological Cancer 13:2, 164-169
CrossRef410
Sara C. Erridge, Nevin Murray. (2003) Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation. Seminars in Oncology 30:1, 26-37
CrossRef411
Achim Schneider, Lutz Gissmann. (2003) Cervical Cancer. American Journal of Cancer 2:4, 253-268
CrossRef412
Yago Nieto. 2003. DNA-binding agents. , 171-209.
CrossRef413
S Pecorelli, R Angioli, G Favalli, F Odicino. 2003. Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium. , 565-584.
CrossRef414
Claude Koren, Rinat Yerushalmi, Alan Katz, Hana Malik, Aaron Sulkes, Eyal Fenig. (2002) Hypersensitivity Reaction to Cisplatin During Chemoradiation Therapy for Gynecologic Malignancy. American Journal of Clinical Oncology 25:6, 625-626
CrossRef415
Syed A Hussain, Nicholas D James. (2002) Organ preservation strategies in bladder cancer. Expert Review of Anticancer Therapy 2:6, 641-651
CrossRef416
D HOLTZ, C DUNTON. (2002) Traditional management of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 29:4, 645-657
CrossRef417
S IM, B MONK. (2002) New developments in the treatment of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 29:4, 659-672
CrossRef418
Henry Kitchener. (2002) Evidence-based medicine applied to cervical cancer. Virus Research 89:2, 175-181
CrossRef419
Rachel Kupets, Gillian M. Thomas, Allan Covens. (2002) Is There a Role for Pelvic Lymph Node Debulking in Advanced Cervical Cancer?. Gynecologic Oncology 87:2, 163-170
CrossRef420
D.T. Rein, C.M. Kurbacher, M. Breidenbach, T. Schöndorf, T. Schmidt, E. König, U.-J. Göhring, J.-U. Blohmer, P. Mallmann. (2002) Weekly Carboplatin and Docetaxel for Locally Advanced Primary and Recurrent Cervical Cancer: A Phase I Study. Gynecologic Oncology 87:1, 98-103
CrossRef421
Tarik Belhocine, Alain Thille, Viviana Fridman, Adelin Albert, Laurence Seidel, Philippe Nickers, Frederic Kridelka, Pierre Rigo. (2002) Contribution of Whole-Body 18FDG PET Imaging in the Management of Cervical Cancer. Gynecologic Oncology 87:1, 90-97
CrossRef422
L. T. Soh, D. Heng, I. W. Lee, T. H. Ho, K. M. Hui. (2002) The relevance of oncogenes as prognostic markers in cervical cancer. International Journal of Gynecological Cancer 12:5, 465-474
CrossRef423
Panos T Lappas, Peter G Rose. (2002) Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review. Expert Opinion on Pharmacotherapy 3:9, 1245-1249
CrossRef424
P.O. Witteveen, M.J. Verhaar, I.M. Jürgenliemk-Schulz, M.A. van Eijkeren. (2002) Update on the treatment of advanced cervical cancer. Critical Reviews in Oncology/Hematology 43:3, 245-256
CrossRef425
A. Duenas-Gonzalez. (2002) Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. Annals of Oncology 13:8, 1212-1219
CrossRef426
H. Lukka, H. Hirte, A. Fyles, G. Thomas, L. Elit, M. Johnston, M. Fung Kee Fung, G. Browman. (2002) Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer–a Meta-analysis. Clinical Oncology 14:3, 203-212
CrossRef427
Liliana Vitali, J.Sebastian Yakisich, Marina Fernanda Vita, Alejandro Fernandez, Liliana Settembrini, Åke Siden, Mabel Cruz, Hector Carminatti, Oscar Casas, Victor Idoyaga Vargas. (2002) Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Letters 180:1, 7-12
CrossRef428
K. Fujiwara, S. Suzuki, E. Yoden, H. Ishikawa, Y. Imajo, I. Kohno. (2002) Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. International Journal of Gynecological Cancer 12:3, 250-256
CrossRef429
Richard R Barakat, Hedvig Hricak. (2002) What do we expect from imaging?. Radiologic Clinics of North America 40:3, 521-526
CrossRef430
Alexander D Guminski, Paul R Harnett, Anna deFazio. (2002) Scientists and clinicians test their metal–back to the future with platinum compounds. The Lancet Oncology 3:5, 312-318
CrossRef431
Dennis R. Scribner, Doris M. Benbrook. (2002) Retinoids Enhance Cisplatin-Based Chemoradiation in Cervical Cancer Cells in Vitro. Gynecologic Oncology 85:1, 223-225
CrossRef432
Adolf E. Schindler. (2002) Hormone replacement therapy (HRT) in women after genital cancer. Maturitas 41, 105-111
CrossRef433
Charles J. Dunton, Stephanie A. King, Julia Neufeld, Jorge Tolosa, Gonzalo Perez, Andres Avila, Kelly Underhill. (2002) Phase I Study of Topotecan and Radiation Therapy in Advanced Cervical Cancer. Gynecologic Oncology 85:1, 185-187
CrossRef434
David H. Moore. (2002) The role of radical hysterectomy and neoadjuvant chemotherapy in carcinoma of the cervix. Current Oncology Reports 4:2, 145-151
CrossRef435
Giovanni Scambia. (2002) To the Editor. Gynecologic Oncology 85:1, 226-227
CrossRef436
Stephanie V. Blank, Stephen C. Rubin, George Coukos, Kunjlata M. Amin, Steven M. Albelda, Katherine L. Molnar-Kimber. (2002) Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation. Human Gene Therapy 13:5, 627-639
CrossRef437
T. Uno, H. Ito, J. Itami, T. Sato, S. Minoura, S. Yasuda, T. Aruga, K. Isobe, N. Shigematsu, A. Kubo. (2002) Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix. International Journal of Gynecological Cancer 12:2, 187-191
CrossRef438
C. Beskow, A.-K. Agren-Cronqvist, F. Granath, B. Frankendal, R. Lewensohn. (2002) Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989-1991. International Journal of Gynecological Cancer 12:2, 158-170
CrossRef439
Jayanthi S. Lea, Ellen E. Sheets, Linda R. Duska, David S. Miller, John O. Schorge. (2002) Early-Stage Cervical Adenocarcinoma Treated by Surgical Intent: The Role of Para-aortic Lymph Node Dissection. Gynecologic Oncology 84:2, 285-288
CrossRef440
Numa Cellini, Alessio G Morganti, Gabriella Macchia, Vincenzo Valentini, Stefano Luzi, Daniela Smaniotto. (2002) Chemoradiation in cervical carcinoma: a must?. Expert Review of Anticancer Therapy 2:1, 83-89
CrossRef441
Annette Hasenburg, Joseph K. Salama, T.John Van, Chad Amosson, J.Kam Chiu, Dirk G. Kieback. (2002) Evaluation of Patients after Extraperitoneal Lymph Node Dissection and Subsequent Radiotherapy for Cervical Cancer. Gynecologic Oncology 84:2, 321-326
CrossRef442
F. Foroudi, C.A. Bull, V. Gebski. (2002) Radiation Therapy for Cervix Carcinoma: Benefits of Individualized Dosimetry. Clinical Oncology 14:1, 43-49
CrossRef443
Yoichi Aoki, Kenichi Tanaka. (2002) Current approaches of neoadjuvant chemotherapy in cervical cancer. Expert Review of Anticancer Therapy 2:1, 73-82
CrossRef444
Jayanthi S. Lea, Ellen E. Sheets, Robert M. Wenham, Linda R. Duska, Robert L. Coleman, David S. Miller, John O. Schorge. (2002) Stage IIB–IVB Cervical Adenocarcinoma: Prognostic Factors and Survival. Gynecologic Oncology 84:1, 115-119
CrossRef445
Masahiro Sasaoka, Nobukazu Fuwa, Akiko Asano, Akira Matsumoto, Eriko Katou, Yoshiyuki Ito. (2001) Patterns of Failure in Carcinoma of the Uterine Cervix Treated With Definitive Radiotherapy Alone. American Journal of Clinical Oncology 24:6, 586-590
CrossRef446
J BASIL. (2001) CERVICAL CARCINOMAContemporary Management. Obstetrics and Gynecology Clinics of North America 28:4, 727-742
CrossRef447
Craig MacLeod, Anne O'Donnell, Martin HN Tattersall, Chris Dalrymple, Ian Firth. (2001) Locally advanced cervix cancer: Chemotherapy prior to definitive surgery or radiotherapy. A single institutional experience. Australasian Radiology 45:4, 491-495
CrossRef448
Hiroshi Tsuda, Masahiro Tanaka, Takao Manabe, Shinichi Nakata, Osamu Ishiko, Kumio Yamamoto. (2001) Phase I-II study of neoadjuvant chemoradiotherapy followed by radical surgery in locally advanced cervical cancer. Anti-Cancer Drugs 12:10, 853-858
CrossRef449
G. Scambia, G. Ferrandina, M. Distefano, A. Fagotti, R. Manfredi, G.F. Zannoni, S. Mancuso. (2001) Is There a Place for a Less Extensive Radical Surgery in Locally Advanced Cervical Cancer Patients?. Gynecologic Oncology 83:2, 319-324
CrossRef450
Daniel T Rein, Christian M Kurbacher. (2001) The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anti-Cancer Drugs 12:10, 787-795
CrossRef451
J Green, J Kirwan, J Tierney, P Symonds, L Fresco, C Williams, M Collingwood. 2001. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. .
CrossRef452
A. Melcher. (2001) Chemoradiation: From the Laboratory to the Clinic*. Clinical Oncology 13:5, 356-360
CrossRef453
Michael Milosevic, Anthony Fyles, Richard Hill. (2001) Interstitial Fluid Pressure in Cervical Cancer. American Journal of Clinical Oncology 24:5, 516-521
CrossRef454
Arno J. Mundt, John C. Roeske, Anthony E. Lujan, S.Diane Yamada, Steve E. Waggoner, Gini Fleming, Jacob Rotmensch. (2001) Initial Clinical Experience with Intensity-Modulated Whole-Pelvis Radiation Therapy in Women with Gynecologic Malignancies. Gynecologic Oncology 82:3, 456-463
CrossRef455
John A Green, John M Kirwan, Jayne F Tierney, Paul Symonds, Lydia Fresco, Mandy Collingwood, Christopher J Williams. (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet 358:9284, 781-786
CrossRef456
PERRY W. GRIGSBY, THOMAS J. HERZOG. (2001) Current Management of Patients With Invasive Cervical Carcinoma. Clinical Obstetrics and Gynecology 44:3, 531-537
CrossRef457
Andreas Obermair, Robyn Cheuk, Keith Horwood, Monika Janda, Barbara Bachtiary, Barbara Schwanzelberger, Alexander Stoiber, James L. Nicklin, Lewis C. Perrin, Alex J. Crandon. (2001) Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. Cancer 92:4, 903-908
CrossRef458
Rachel Kupets, Allan Covens. (2001) Is the International Federation of Gynecology and Obstetrics Staging System for Cervical Carcinoma able to predict survival in patients with cervical carcinoma?. Cancer 92:4, 796-804
CrossRef459
Rachelle Lanciano. (2001) OPTIMIZING RADIATION TREATMENT FOR CERVICAL CANCER. Surgical Clinics of North America 81:4, 859-870
CrossRef460
John D. Hainsworth, Howard A. Burris, Anthony A. Meluch, Margaret N. Baker, Lisa H. Morrissey, F. Anthony Greco. (2001) Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas. Cancer 92:3, 642-649
CrossRef461
Juan E. Sardi. (2001) NEOADJUVANT CHEMOTHERAPY IN GYNECOLOGIC ONCOLOGY. Surgical Clinics of North America 81:4, 965-985
CrossRef462
Arno J. Mundt, Jacob Rotmensch, Steven E. Waggoner, Diane Yamada, Sister Carole Langhauser, Gini F. Fleming. (2001) Phase I Trial of Concomitant Vinorelbine, Paclitaxel, and Pelvic Irradiation in Cervical Carcinoma and Other Advanced Pelvic Malignancies. Gynecologic Oncology 82:2, 333-337
CrossRef463
FH Gastrell, HD Brasch, CA Johnson, PB Bethwaite, DT McConnell. (2001) Malignant mixed Müllerian tumour of the cervix treated with concurrent chemoradiation. The Australian and New Zealand Journal of Obstetrics and Gynaecology 41:3, 352-354
CrossRef464
Y Aubard. (2001) Ovarian tissue cryopreservation and gynecologic oncology: a review. European Journal of Obstetrics & Gynecology and Reproductive Biology 97:1, 5-14
CrossRef465
Satoru Motoyama, Satoshi Takeuchi, Shinya Hamana, Yonson Ku, Yoshiya Miyahara, Yoichi Tateiwa, Shigeki Yoshida, Takeshi Maruo. (2001) Super High-Dose Intraarterial Cisplatin Infusion Under Percutaneous Pelvic Perfusion With Extracorporeal Chemofiltration for Advanced Uterine Cervical Carcinoma. American Journal of Clinical Oncology 24:3, 247-250
CrossRef466
P. Pattaranutaporn, C. Thirapakawong, Y. Chansilpa, S. Therasakvichya, N. Ieumwananontachai, K. Thephamongkhol. (2001) Phase II Study of Concurrent Gemcitabine and Radiotherapy in Locally Advanced Stage IIIB Cervical Carcinoma. Gynecologic Oncology 81:3, 404-407
CrossRef467
C. Lopez-Graniel, M. Reyes, G. Chanona, A. Gonzalez, E. Robles, A. Mohar, H. Lopez-Basave, J. G. De La Garza, A. Duenas-Gonzalez. (2001) Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma. International Journal of Gynecological Cancer 11:3, 210-217
CrossRef468
Nadeem R. Abu-Rustum, Suzette Lee, Arturo Correa, L.Stewart Massad. (2001) Compliance with and Acute Hematologic Toxic Effects of Chemoradiation in Indigent Women with Cervical Cancer. Gynecologic Oncology 81:1, 88-91
CrossRef469
Susan M. Ascher, Junko Takahama, Reena C. Jha. (2001) Staging of Gynecologic Malignancies. Topics in Magnetic Resonance Imaging 12:2, 105-129
CrossRef470
Erik A. Boss, Leon F.A.G. Massuger, Luc A.M. Pop, Lia C.G. Verhoef, Henk-Jan Huisman, Henk Boonstra, Jelle O. Barentsz. (2001) Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma. Journal of Magnetic Resonance Imaging 13:4, 600-606
CrossRef471
Benjamin Tham, Mahesh Parmar. (2001) Current and future trends in randomised trials in gynaecological oncology. The Obstetrician & Gynaecologist 3:2, 61-68
CrossRef472
Ronald J. Place, Sharon G. Gregorcyk, Philip J. Huber, Clifford L. Simmang. (2001) Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Diseases of the Colon & Rectum 44:4, 506-512
CrossRef473
Peter G. Rose. (2001) Locally advanced cervical cancer. Current Opinion in Obstetrics and Gynecology 13:1, 65-70
CrossRef474
Jan H. Schornagel, Marcel Verheij, Harry Bartelink. (2001) Concurrent chemotherapy and radiation for locally advanced squamous cell cancers: what is the schedule of choice?. Current Oncology Reports 3:1, 1-2
CrossRef475
Jeffrey D. Bloss. (2001) Chemotherapy for advanced or recurrent carcinoma of the cervix. Current Oncology Reports 3:1, 33-40
CrossRef476
Marcela G. del Carmen, James F. McIntyre, Arlan F. Fuller, Najmosama Nikrui, Annekathryn Goodman. (2000) Intraoperative Radiation Therapy in the Treatment of Pelvic Gynecologic Malignancies: A Review of Fifteen Cases. Gynecologic Oncology 79:3, 457-462
CrossRef477
Peter G. Rose. (2000) Chemoradiotherapy. Drugs 60:6, 1239-1244
CrossRef478
Charles W. Whitney, Frederick B. Stehman. (2000) The Abandoned Radical Hysterectomy: A Gynecologic Oncology Group Study. Gynecologic Oncology 79:3, 350-356
CrossRef479
Walter Beerheide, Mui Mui Sim, Yee-Joo Tan, Hans-Ulrich Bernard, Anthony E Ting. (2000) Inactivation of the human papillomavirus-16 e6 oncoprotein by organic disulfides. Bioorganic & Medicinal Chemistry 8:11, 2549-2560
CrossRef480
Carlos T. Vallejo, Juan E. P??rez, Mar??a E. Dom??nguez, Bernardo A. Leone, Mario R. Machiavelli, Juan A. Lacava, Alberto O. Romero, Eduardo H. Ortiz, Sergio Grasso, Sonia Amato, Ricardo Rodr??guez, Mario Barbieri, Juan Romero Acu??a, Guillermo Focaccia, Guillermo Suttora, Mirna Scenna, Jos?? M. Boughen, Luis A. Romero Acu??a, Mario J. Langhi. (2000) Neoadjuvant Chemotherapy With Ifosfamide, Cisplatin, and Vinorelbine in Advanced Squamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology: Cancer Clinical Trials 23:5, 481-486
CrossRef481
(2000) Guidelines for Referral to a Gynecologic Oncologist: Rationale and Benefits. Gynecologic Oncology 78:3, S1-S13
CrossRef482
Salvatore Mancuso, Daniela Smaniotto, Pierluigi Benedetti Panici, Barbara Favale, Stefano Greggi, Riccardo Manfredi, P.Alessandro Margariti, Alessio G. Morganti, Giovanni Scambia, Francesca Tortoreto, Vincenzo Valentini, Numa Cellini. (2000) Phase I–II Trial of Preoperative Chemoradiation in Locally Advanced Cervical Carcinoma. Gynecologic Oncology 78:3, 324-328
CrossRef483
Patricia J. Eifel. (2000) Chemoradiation for Carcinoma of the Cervix: Advances and Opportunities. Radiation Research 154:3, 229-236
CrossRef484
Richard C. Boronow. (2000) The Bulky 6-cm Barrel-Shaped Lesion of the Cervix: Primary Surgery and Postoperative Chemoradiation. Gynecologic Oncology 78:3, 313-317
CrossRef485
Kenneth B. Roberts, Nelson Urdaneta, Raul Vera, Andres Vera, Enrique Gutierrez, Yadelis Aguilar, Sara Ott, Ivonne Medina, Pilar Sempere, Sara Rockwell, Alan C. Sartorelli, Diana B. Fischer, James J. Fischer. (2000) Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. International Journal of Cancer 90:4, 206-223
CrossRef486
Seung Jo Kim. (2000) Recent Advances in the Management of Gynecologic Cancers. Journal of Obstetrics and Gynaecology Research 26:4, 235-251
CrossRef487
J VERWEIJ, M DEJONGE. (2000) Achievements and future of chemotherapy. European Journal of Cancer 36:12, 1479-1487
CrossRef488
Craig McLeod, Philip Beale, Martin Tattersall, Chris Dalrymple, Ken Atkinson, Jonathon Carter. (2000) Early results of chemo-radiotherapy for the definitive treatment of cervix cancer. The Australian and New Zealand Journal of Obstetrics and Gynaecology 40:3, 341-342
CrossRef489
Peter G Rose, Panos T Lappas. (2000) Analysis of the Cost Effectiveness of Concurrent Cisplatin-Based Chemoradiation in Cervical Cancer: Implications from Five Randomized Trials. Gynecologic Oncology 78:1, 3-6
CrossRef490
Ruud E. van Rijswijk, Jan B. Vermorken. (2000) Drug Therapy for Gynaecological Cancer in Older Women. Drugs & Aging 17:1, 13-32
CrossRef491
Laurie Elit, Amiram Gafni, Mark N. Levine. (2000) Better Treatments That Cost More: The Dilemma. Gynecologic Oncology 78:1, 1-2
CrossRef492
Jacob Rotmensch, Philip P. Connell, Diane Yamada, Steve E. Waggoner, Arno J. Mundt. (2000) One versus Two Intracavitary Brachytherapy Applications in Early-Stage Cervical Cancer Patients Undergoing Definitive Radiation Therapy. Gynecologic Oncology 78:1, 32-38
CrossRef493
P. Morice, C. Haie-Meder, A. Rey, P. Pautier, C. Lhomme, A. Gerbaulet, P. Duvillard, D. Castaigne. (2000) Radiotherapy and radical surgery for treatment of patients with bulky stage IB and II cervical carcinoma. International Journal of Gynecological Cancer 10:3, 239-246
CrossRef494
R Symonds. (2000) The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. European Journal of Cancer 36:8, 994-1001
CrossRef495
Xiang Gao. (2000) Adjuvant Chemotherapy or Radiotherapy in Cervical Cancer. Gynecologic Oncology 77:2, 340-341
CrossRef496
Yoichi Aoki, Masaru Sasaki, Minoru Watanabe, Takaaki Sato, Ikunosuke Tsuneki, Hiroshi Aida, Kenichi Tanaka. (2000) High-Risk Group in Node-Positive Patients with Stage IB, IIA, and IIB Cervical Carcinoma after Radical Hysterectomy and Postoperative Pelvic Irradiation. Gynecologic Oncology 77:2, 305-309
CrossRef497
Susan K. Gibbons, Henry M. Keys. (2000) Advanced cervical cancer. Current Treatment Options in Oncology 1:2, 157-160
CrossRef498
Merideth C. Kamradt, Najeeb Mohideen, Andrew T.M. Vaughan. (2000) RU486 Increases Radiosensitivity and Restores Apoptosis through Modulation of HPV E6/E7 in Dexamethasone-Treated Cervical Carcinoma Cells. Gynecologic Oncology 77:1, 177-182
CrossRef499
Karen H. Lu, Thomas W. Burke. (2000) Early cervical cancer. Current Treatment Options in Oncology 1:2, 147-155
CrossRef500
A Uitterhoeve. (2000) Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer results of the EORTC 08912 phase I/II study. European Journal of Cancer 36:5, 592-600
CrossRef501
Pamela J. Paley, Barbara A. Goff, Richard Minudri, Benjamin E. Greer, Hisham K. Tamimi, Wui-Jin Koh. (2000) The Prognostic Significance of Radiation Dose and Residual Tumor in the Treatment of Barrel-Shaped Endophytic Cervical Carcinoma. Gynecologic Oncology 76:3, 373-379
CrossRef502
Y NAGATA, N ARAKI, H KIMURA, K FUJIWARA, K OKAJIMA, T AOKI, M MITSUMORI, K SASAI, M HIRAOKA, T HIGUCHI. (2000) Neoadjuvant Chemotherapy by Transcatheter Arterial Infusion Method for Uterine Cervical Cancer. Journal of Vascular and Interventional Radiology 11:3, 313-319
CrossRef503
Michael E. Hagensee. (2000) Infection with human papillomavirus: Update on epidemiology, diagnosis, and treatment. Current Infectious Disease Reports 2:1, 18-24
CrossRef504
S K. Vinod, C A. MacLeod, C Dalrymple, P Elliott, K Atkinson, J Carter, I Firth. (2000) Surgery and post-operative radiotherapy for early stage cervical cancer. The Australian and New Zealand Journal of Obstetrics and Gynaecology 40:1, 66-69
CrossRef505
Hiroyoshi Yuki, Masaki Fujimura, Yoshihiro Yamakawa, Takao Hidaka, Shigeru Saito. (2000) Detection of Apoptosis and Expression of Apoptosis-associated Proteins as Early Predictors of Prognosis after Irradiation Therapy in Stage IIIb Uterine Cervical Cancer. Cancer Science 91:1, 127-134
CrossRef506
Benjamin Piura, Alex Rabinovich, Mihai Meirovitz, Ilana Yanai-Inbar. (1999) Glassy cell carcinoma of the uterine cervix. Journal of Surgical Oncology 72:4, 206-210
CrossRef507
N.S. Russell, H. Bartelink. (1999) Radiotherapy: the last 25 years. Cancer Treatment Reviews 25:6, 365-376
CrossRef508
R.P. Symonds. (1999) Concurrent chemotherapy and radiotherapy: An affordable important improvement in the treatment of advanced cervical cancer. Medical and Pediatric Oncology 33:5, 493-496
CrossRef509
R. J. Cardosi, M. B. Reedy, J. R. Van Nagell, S. E. Spires. (1999) Neuroendocrine signet ring cell adenocarcinoma of the endocervix. International Journal of Gynecological Cancer 9:5, 433-437
CrossRef510
Sandra E. Brooks, Katie E. Wakeley. (1999) Current trends in the management of carcinoma of the cervix, vulva, and vagina. Current Opinion in Oncology 11:5, 383
CrossRef511
A. Duenas-Gonzalez, F. U. Lara-Medina, G. Solorza-Luna, A. Mota-Garcia, J. De la garza-Salazar, P. J. Sobrevilla-Calvo. (1999) Adjuvant high-dose chemotherapy supported by peripheral blood stem cell transplantation for high-risk cervical carcinoma. International Journal of Gynecological Cancer 9:4, 333-336
CrossRef512
Jürgen Dunst, Rolf Sauer. (1999) Simultane radiochemotherapie mit cisplatin verbessert überleben bei patientinnen mit zervixkarzinom. Strahlentherapie und Onkologie 175:6, 257-258
CrossRef513
Thomas, Gillian M., . (1999) Improved Treatment for Cervical Cancer — Concurrent Chemotherapy and Radiotherapy. New England Journal of Medicine 340:15, 1198-1200
Full Text514
Morris, Mitchell, Eifel, Patricia J., Lu, Jiandong, Grigsby, Perry W., Levenback, Charles, Stevens, Randy E., Rotman, Marvin, Gershenson, David M., Mutch, David G., . (1999) Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer. New England Journal of Medicine 340:15, 1137-1143
Full Text515
Jeanne M. Schilder, Frederick B. Stehman. (1999) Concurrent chemotherapy and radiation therapy in primary cancer of the cervix. Current Oncology Reports 1:1, 41-46
CrossRef
